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1. Introduction 
 
1.1 Sorsby fundus dystrophy 
Sorsby fundus dystrophy (SFD) is a rare autosomal dominant disorder affecting 
the central retina, the region responsible for high resolution and colour vision. The 
disease generally manifests in the fourth decade of life, with rapid loss of central vision 
followed by progressive loss of peripheral vision, ultimately leading to blindness 
(Sorsby et al., 1949). The main histopathological features are deposits of lipofuscin-like 
material (known as drusen) and thickening of Bruch’s membrane. As the disorder 
progresses, there is subretinal neovascularization, peripheral atrophy of the retinal 
pigment epithelium, and later atrophy of the choriocapillaris. SFD has phenotypic 
resemblances with age related macular degeneration (AMD), a complex retinal disease 
with a multifactorial genesis. AMD is the most common cause of late-onset blindness in 
the elderly of developed countries (Klein et al., 1992). 
In affected individuals a heterozygous point mutation in the tissue inhibitor of 
metalloproteinases-3 (TIMP3) gene has been identified (Weber et at., 1994). So far, 
several point mutations in TIMP3 have been reported, all localized in the C-terminal 
domain of the protein. Of these, the majority result in unpaired cysteine residues in the 
mature protein, namely S156C (Felbor et al., 1995), G166C (Felbor et al., 1997), 
G167C (Jacobson et al., 1995), Y168C (Weber et al., 1994), S170C (Barbazetto et al., 
2005), Y172C (Jacobson et al., 2002) or S181C (Weber et al., 1994). Another existing 
mutation introduces a stop codon (E139X), deleting a segment from the C-terminal of 
TIMP3 (Clarke et. al., 2001). A splice site mutation at the intron 4/exon 5 junction of 
TIMP3 has been reported in two Japanese families (Tabata et al., 1998). More recently, 
a non-cysteine mutation in the TIMP3 gene was identified which replaces His at 
position 158 with an Arg residue (Lin et al., 2006). 
 
1.2 Structure and function of the retina  
The human eye is a highly complex photosensitive organ of neuronal origin, 
having several important layers in its structure which facilitate high resolution vision 
(Fig. 1). In the outer layer of the eye wall the sclera and cornea are found, which have 
protective roles for the inner part of the eye. The cornea, together with the crystalline 
lens, focuses the light which enters the eye onto the photoreceptor cells in the retina. 
The intermediate layer of the eye is represented by the choroid which includes the the 
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iris, lens, ciliary body, and the pupil. The ciliary body is attached to the lens for 
protection and changes the shape of the lens to modify the focus of the eye. The iris 
generates the colour of the eye and allows light to pass to the retina. The circular muscle 
in the iris controls the size of the pupil and thus regulates the intensity of light that 
reaches the retina. The lens together with the cornea allows the eye to focus on objects 
at various distances and generates a sharp image on the retina.  
Figure 1. Vertical section of a human eye (Taken from http://webvision.med.utah.edu/anatomy.html) 
The inner layer of the eye is the retina and is composed of many types of cell which 
form several retinal layers (Fig.2). The photoreceptors comprise two types of cells: rods 
and cones, with major functional differences between them. Cones provide the eye with 
colour sensitivity, and function well in bright light; while rods are more sensitive and 
are responsible for dark-adapted vision. The outer plexifrom layer is the region where 
synapses are formed between photoreceptors and bipolar and horizontal cell dendrites. 
The inner plexiform layer is also an area of synapses where the bipolar and amacrine 
cells are linked to the ganglion cells. The retinal pigment epithelium (RPE) forms the 
outer blood-retinal barrier and plays a central role in retinal physiology by carrying out 
phagocytosis of the outer segment of photoreceptor cells, storage and synthesis of trans-
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retinal (or vitamin A) and transporting metabolites, thus supporting the function of the 
photoreceptors (Rizzolo, 1997) 
 
Figure 2. Schematic representation of the cell layers found in the structure of the retina (Taken from 
Kolb, 2003) 
 
 
1.3 The extracellular matrix (ECM) 
 The ECM is a highly complex structure that serves as a scaffold to stabilise the 
physical structure of tissues and regulate the behaviour of cells by influencing 
apoptosis, migration, proliferation, development, shape and function (Alberts et al., 
1994). The ECM is secreted locally by specialized types of cells such as fibroblasts, 
chondroblasts, and osteoblasts. The macromolecules found in matrix can be divided in 
two main classes: fibrous proteins such as collagen, elastin, fibronectin and laminin, and 
proteoglycans with glycosaminoglycans (GAGs) which are covalently linked to core. 
Glycosaminoglycans are built from repeating disaccharide units consisting of one 
sulfated sugar (N-acetylglucosamine or N-acetylgalactosamine) and a second sugar 
related to uronic acid (glucuronic or iduronic). Four groups of glycosaminoglycans are 
found in the ECM: (i) hyaluronan, (ii) chondroitin and dermatan sulfate, (iii) heparan 
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sulfate, and (iv) keratan sulfate (Alberts et al., 1994), which are distinguished by the 
type and linkage of the sugar and the number and the position of the sulphur atom. 
Because polysaccharide chains are highly negatively charged due to sulfate or carboxyl 
groups they attract cations and are able to retain large amounts of water. This enables 
the ECM to withstand compressive forces and at the same time provides mechanical 
support for tissue. 
Hyaluronan, unlike the other three groups of GAGs, does not contain a sulfur atom in its 
structure and is not linked covalently to any core protein (Toole, 2000). Functionally, it 
is involved in the facilitation of cell migration during tissue morphogenesis and repair 
(Oliferenko et al., 2000; Bourguignon et al., 2000; Evanko et al., 1999). It is produced 
in response to injury where it mediates wound healing and is important in joint motility 
as a lubricant. Tissue specific functions of hyaluronan are given by its interaction with 
other matrix components such as proteins (either glycosylated or non glycosylated) 
from the matrix as well as membrane anchored cell surface proteins. 
Proteoglycans have major roles in intercellular biochemical signalling such as binding 
of fibroblast growth factors (FGFs) to heparan sulfate chains causing oligomerization of 
the growth factors and leading to the activation of cell surface tyrosine kinase receptors 
(Iozzo, 1998). Proteoglycans can also bind other types of secreted proteins including 
proteases and their inhibitors, in this way modulating their activity. In the case of 
inflammation, heparan sulfate proteoglycans sequester secreted chemokines and 
stimulate white blood cells to migrate into inflamed tissue from the bloodstream. The 
heparan sulfate proteoglycan percalan is found in the structure of the basal lamina of the 
kidney glomerulus where it participates in filtering molecules passing into the urine 
from the bloodstream. Some proteoglycans are integral components of the plasma 
membrane whereas others are bound to the surface of the lipid bilayer by a 
glycosylphosphatidylinositol (GPI) anchor and act as coreceptors (Bernfield et al., 
1999). The plasma membrane proteoglycan syndecan belongs to this category and binds 
several types of proteins, including FGFs, integrins and fibronectins.  
The collagens are the most abundant matrix proteins in mammals (Prockop & 
Kivirikko, 1995). There are about 20 different types of collagen known. The primary 
structure of a typical collagen is a triple helix in which 3 alpha helical chains are wound 
around one another to form a superhelix. Collagens are very rich in proline and glycine 
residues which have an important role in the assembly of this triple helix structure. 
Glycine is found at every third position of the alpha chain and allows the three alpha 
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helical chains to pack tightly to form the collagen superhelix. This provides tensile 
strength. Proline and lysine in the collagen are hydroxylated, contributing to the 
stabilization of the triple helix by forming interchain hydrogen bonds. These 
interactions in the triple helix give a rope like structure called fibrilar collagens. In the 
extracellular space some collagens can assemble into higher order polymers called 
collagen fibrils which can further self-organize into even higher order structures known 
as collagen fibers. This category of collagens includes collagen types I, II, III, V, and 
XI. Collagen type IX and XII are fibril associated collagens, making the link between 
the fibrils and other matrix components. Collagen type IV forms a meshwork and is 
found in the structure of the basal lamina. Collagen type VII is organized in structures 
called anchoring fibrils which link the basal lamina to the underlying connective tissue. 
Type IV and VII collagen are also called network-forming collagens. Collagen type 
XVII is anchored at the cell surface by a transmembrane domain and is found in 
hemidesmosomes. Collagen type XVIII is localized in the basal lamina of blood vessels. 
Cleavage at its C-terminal domain leads to the production of endostatin, a peptide with 
antiangiogenic properties (Zatterstrom et al., 2000). 
Elastic fibers are important components of the extracellular matrix of tissues such as 
skin, blood vessel and lung and provide the required elasticity for these organs 
(Debellea & Tamburro, 1999). The principal component of elastic fiber is elastin which 
is composed of stretches of hydrophobic segments (which give the elastic properties) 
alternating with alanine and lysine rich α-helical segments involved in the formation of 
links between molecules. In the structure of elastic fibers microfibrils composed of a 
number of different proteins can be found. Fibrilin, a well characterized glycoprotein, 
binds to elastin and has a protective role for the integrity of elastic fiber. 
Other classes of ECM proteins are involved in attachment and organization of cells. 
One of the best characterized proteins from this category is fibronectin, which is a large 
glycoprotein composed of disulfide liked dimers (Schwarzbauer & Sechler, 1999). It 
can be found in both soluble and fibrilar forms due to alternate splicing of the gene. 
Soluble fibronectin circulates in the blood stream where it is involved in blood clotting, 
wound healing and phagocytosis. Fibrilar fibronectin is a component of the ECM and is 
associated with cell surface molecules and involved in guiding cell migration in 
vertebrate embryos. 
Laminin, another important component of the ECM, is a component of basal lamina 
where it has diverse functions (Colognato & Yurchenco, 2000). Structurally, laminin is 
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composed of three long polypeptide chains (α,β,γ) that are disulfide-bonded into an 
asymmetric structure. Laminin in the basement membrane can bind to several proteins. 
One domain interacts with percalan, another with nidogen and another can bind to cell 
surface receptors. Basal lamina, besides its filtering role in the kidney glomerula, is 
involved in cell metabolism, polarity, migration, proliferation and differentiation. 
 
1.4 Mouse models of TIMP3 mutations 
Mouse models provide important tools to study and dissect the function of a 
gene both in health and disease. Although yeast, worms, and flies are suitable models to 
study various biological processes, a major advantage of the mouse is its similarities 
with humans at the genetic (approximately, 80-90% homology) and the physiological 
level. Therefore murine models can be used to study human diseases, providing useful 
information about the function of a gene/gene product or the mechanism of a disease. 
Towards this end, an important advance was the generation of transgenic mice by 
insertion of a foreign gene in the mouse germline. An alternative approach was to 
generate knock-out mice by homologous recombination (Thomas et al., 1987). 
Generation of knock-in animals allows the alteration of a certain(s) amino acid(s) at a 
precise position in a specific gene. The advantage of a gene targeting strategy is that the 
mouse gene is modified in its natural location representing a very good in vivo model. 
However, there are limitations of the knock-out technology since in some cases (10-
15%) the inactivation of a gene leads to lethality of the embryo thus making it 
impossible to study the function of the respective gene. To overcome this situation so-
called conditional knock-out mice were developed (Gu et al., 1994; Gu et al., 1993, 
Rajewsky et al., 1996). Conditional gene targeting can be achieved by crossing the 
mutant mouse line with Cre transgenic mice in which the Cre recombinase is under 
strict cell type specific and/or inducible promoter control. 
 
1.4.1 TIMP3 knock-out mouse  
This mouse model was generated by our group (Soboleva et al., 2003, Janssen et 
al., 2008) and independently by a US laboratory (Leco et al., 2001). These mice show 
several pathological features such as development of spontaneous air space enlargement 
in the lungs, probably due to enhanced MMP-mediated ECM degradation (Leco et al., 
2001), accelerated apoptosis of epithelial cells in the mammary gland (Fata et al., 2001), 
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dilated cardiomyopathy (Fedak et al., 2004) and chronic hepatic inflammation 
(Mohammed et al., 2004). 
 
1.4.2 TIMP3 Ser156Cys knock-in mouse  
A targeted knock-in mouse model for SFD was generated in house and 
characterized by Weber et al., 2002. This mouse line carries a Ser156Cys mutation in 
the endogenous Timp3 of the mouse. This homologuous mutation was associated with 
SFD in a large pedigree (Felbor et al., 1995). Phenotypically, the knock-in mouse shows 
several abnormalities in Bruch’s membrane and the RPE. At the biochemical level, 
typical high molecular weight complexes of S156C-TIMP3 mutant protein can be 
observed under non-reducing conditions (Weber et al., 2002; Yeow et al., 2002).  
 
1.5 Structure of the tissue inhibitors of metalloproteinases (TIMPs) 
The activity of proteolytic enzymes in the extracellular space must be controlled 
in a homeostatic way to avoid uncontrolled turnover of ECM components. Cells are 
endowed with several mechanisms which allow them to keep the anabolism and 
catabolism of the ECM in equilibrium. One of these mechanisms is that proteases are 
biosynthesized in an inactive form, called a proform or zymogen, which needs to be 
activated, usually by cleavage of the propeptide from the zymogen. Specific control of 
proteinase activity is achieved by a family of proteins known as tissue inhibitors of 
metalloproteinases (TIMPs). 
The TIMPs are a family of secreted proteins comprising four members (TIMP1, -2, -3, -
4), which are endogenous inhibitors of a variety of extracellular proteases. They form 
tight stoichiometric noncovalent 1:1 complexes with proteases, which are resistant to 
various proteolytic treatments. The TIMPs share about 40 % identity at the primary 
amino acid sequence structure. A common feature of the TIMPs is that they contain 12 
evolutionary conserved cysteine residues which contribute to the formation of 6 
disulfide bonds. TIMPs have a rigid structure which is held together by these 6 
intramolecular disulfide bonds and fold into two distinct independent domains, often 
referred to as the N-terminal and C-terminal domain (Murphy and Willenbrock, 1995). 
Mature mouse TIMP1 is a secreted 181 amino acid glycoprotein with a molecular mass 
of 21 kDa (Docherty et al., 1985). Initially, this inhibitor was found in cultured human 
fibroblasts (Bauer et a., 1975), human serum (Woolley et al., 1975), cartilage and aorta 
(Keuttner et al., 1976).  
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TIMP2 is composed of 192 amino acids and is a soluble non-glycosylated protein with a 
molecular mass of 22 kDa (Stetler-Stevenson et al., 1989; 1990). TIMP2 was first 
identified in rabbit brain capillary endothelial cells treated with 12-O-
tetradecanoylphorbol-13-acetate (Herron et al., 1986). 
TIMP3 was first identified in the ECM of virus transformed chicken embryo fibroblasts 
(Blenis et al., 1983) and is the only family member tightly associated with the ECM 
(Leco et al., 1994). TIMP3 is a 24 kDa glycoprotein with 12 conserved cysteine 
residues which form 6 disulfide bonds. The N-terminal domain is responsible for the 
interaction with a number of proteases and the C-terminal is known to bind to the ECM 
(Langton et al., 1998). However, it has been shown recently that binding of TIMP3 to 
the ECM is mediated by both the N-terminal and the C-terminal of the inhibitor (Lee, et 
al., 2007). 
The last member of the family, TIMP4, was identified by cloning (Greene et al., 1996) 
and has a molecular weight of 23 kDa with 195 amino acids. 
 
1.6 Biological functions of TIMP3 
Over the last two decades several biological and pathological functions of 
TIMP3 have been demonstrated. These functions can be classified in two groups of 
activity. First, TIMP3 has an inhibitory function towards a variety of proteolytic 
enzymes in the ECM, attributed to the N-terminal domain, and the second, 
nonenzymatical inhibitory activity for which the C-terminal seems to be responsible 
(Langton et al., 1998).  
 
1.6.1 Inhibition of MMPs by TIMP3 
Matrix metalloproteinases (MMPs) are a family of calcium and zinc dependent 
endopeptidases which are responsible for ECM protein turnover and play a key role in 
matrix remodeling. The substrates of these proteases are diverse and include various 
types of collagen and noncollagenous components of the ECM, in this way different 
activation factors important for processes involved in ECM remodeling, such as cell 
adhesion, cell-cell interaction, and cell migration (Table 1) are released. The MMPs are 
expressed as inactive proforms, consisting of a signal sequence (which directs them into 
the extracellular environment), a propeptide that needs to be removed for full biological 
activity, a zinc dependent catalytic domain responsible for substrate cleavage, a hinge 
region and a hemopexin like domain.  
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A subclass of MMPs are represented by the so-called membrane-type MMPs 
(MT-MMPs) (Sato et al., 1994; Cao et al., 1995) which, unlike the classical MMPs, 
contain either a stretch of 20 hydrophobic amino acids, which forms a transmembrane 
domain, and a small cytoplasmic domain (in the case of MMP14, MMP15, MMP16, 
and MMP24) or a glycosylphosphatidyl inositol linkage (for MMP17 and MMP25), 
which anchors these proteinases to the cell surface. Currently, there are approximately 
26 MMPs known, all of which can be inhibited by TIMP3 but also by other TIMP 
family members, although with different binding affinities (Murphy and Willenbrock, 
1995). Therefore, all four TIMPs posess overlapping inhibitory function towards the 
MMPs. This is supported by individual TIMP knock out mice where unaffected MMP 
activities further demonstrate the redundant function of these inhibitors. 
 
 
Table 1. A list of known matrix metalloproteinases (MMPs) and their corresponding 
biological functions. 
 
MMP Alternative names Substrates 
MMP1 Collagenase, Fibroblast 
Collagenase, Interstitial 
Collagenase 
Collagen type I, II, III, VII, VIII, X, 
aggrecan, gelatin MMP2, MMP9 
MMP2 72 kDa Gelatinase, 
Gelatinase A, Type IV 
collagenase, Neutrophil 
gelatinase 
Collagen type I, II, III, IV, VII, X, XI, 
aggrecan, elastin, fibronectin, gelatin, 
laminin,  MMP9, MMP13 
MMP3 Procolagenase, Stromelysin-
1, Transin-1 
Collagen type II, III, IV, IX, X, XI, aggrecan, 
elastin, fibronectin, gelatin, laminin,  MMP8, 
MMP13 
MMP7 Matrilysin, Matrin, Uterine 
metalloproteinase 
Collagen type IV, X, aggrecan, elastin, 
fibronectin, gelatin, laminin,  MMP1, 
MMP2, MMP9 
MMP8 Collagenase-2, Neutrophil 
collagenase, PMNL 
collagenase 
Collagen type II, III, V, VII, VIII, X, 
aggrecan, elastin, fibronectin, gelatin, 
laminin 
MMP9 92 kDa Gelatinase, Type IV Collagen type IV, V, VII, X, XIV, aggrecan, 
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collagenase, Gelatinase B elastin, fibronectin, gelatin 
MMP10 Stromelysin-2, Transin-2 Collagen type III, IV, V, aggrecan, elastin, 
fibronectin, gelatin, laminin, MMP1, MMP8 
MMP11 Stromelysin-2 Aggrecan, fibronectin, laminin 
MMP12 Macrophage metalloelastase Collagen type IV, elastin, fibronectin, 
gelatin, laminin 
MMP13 Collagenase-3 Collagen type I, II, III, IV, aggrecan, gelatin 
MMP14 MT1-MMP Collagen type I, II, III, aggrecan, elastin, 
fibronectin, gelatin, laminin, MMP2, 
MMP13 
MMP15 MT2-MMP fibronectin, gelatin, laminin, MMP2 
MMP16 MT3-MMP Collagen type III, gelatin, fibronectin, MMP2
MMP17 MT4-MMP Fibrin, gelatin 
MMP18 Xenopus Collagenase-4, 
xCol4 
 
MMP19 RASI-1 Collagen type IV, aggrecan, gelatin, 
fibronectin, laminin, COMP 
MMP20 Enamelysin Aggrecan, amelogenin, COMP 
MMP23 Cysteine array MMP  
MMP24 MT5-MMP  
MMP25 MT6-MMP, leukolysin Collagen type IV, gelatin, fibronectin, 
laminin 
MMP26 Matrilysin-2, Endometase gelatin, fibronectin 
MMP28 Epylisin  
 
 
 
1.6.2 Regulation of the activity of ADAMs by TIMP3 
A disintegrin and metalloproteinases (ADAMs) comprise a large family of 
membrane bound proteases consisting of 34 members (Mochizuki and Okada, 2007). 
Structurally, they are composed of a signal sequence, a pro-domain, a metalloproteinase 
or metalloproteinase-like domain, a disintegrin-like domain, a cysteine-rich domain, 
EGF-like repeats, a transmembrane domain, and a cytoplasmic tail. Proteolytically 
active ADAMs are mainly involved in the cleavage of the extracellular domain of the 
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membrane anchored proteins, a process called shedding, although they may also have 
additional functions such as cell-cell fusion, cell adhesion and cell signalling through 
the intracellular domain (Table 2). Unlike the broad selectivity of the TIMPs for all 
MMPs, the ADAMs are inhibited mainly by TIMP3. To date, TIMP3 has been shown to 
inhibit several ADAMs including ADAM10 (Amour et al., 2000), ADAM12 (Loechel 
et al., 2000), ADAM28 (Mochizuki et al., 2004), ADAM33 (Zou et al., 2004). 
However, there are several reports which show that other TIMP family members are 
able to block ADAM activity, although often with lower efficiency, e.g. ADAM10 
(Amour et al., 2000), ADAM28 (Mochizuki et al., 2004), ADAM33 (Zou et al., 2004). 
In this context, a unique inhibitory function of TIMP3 is to block the shedding activity 
of ADAM17 (also known as TNF-alpha converting enzyme, TACE) (Amour et al., 
1998). TACE is involved in the cleavage of membrane anchored TNF-α to its soluble 
form (Black et al., 1997) and has an important role in shedding of many other 
membrane bound proteins (Peschon et al., 1998). Among the other ligands, TIMP3 can 
block TACE mediated ectodomain shedding of syndecan-1 and syndecan-4 (Fitzgerald 
et al., 2000); L-selectin (Borland et al., 1999); and the interleukin-6 receptor 
(Hargreaves et al., 1998). Also, it has been shown that TACE is able to cleave several 
membrane anchored proteins including IL1-RII, IL-15Ra, VCAM-1 (Garton et al., 
2003), GPIba, M-CSFR (Rovida et al., 2001), fractalkine (CX3CL1) (Garton et al., 
2001), c-kit (Cruz et al., 2004), collagen type XVII (Franzke et al., 2002), p55 TNFR1, 
p75 TNFR2, TGFa (Fan et al. 1999), HB-EGF (Sunnarborg et al., 2002), amphiregulin, 
epiregulin, MUC1 (Thathiah et al., 2003), c-Met (Nath et al., 2001; Wajih et al., 2002), 
CD30 (Hansen et al., 2000), CD40 (Contin et al. 2003), HER4/erbB4 (Rio et al. 2000), 
p75 neutrophin receptor (p75NTR)  (Weskamp et al., 2004), TRANCE (Lum et al., 
1999), NRG (Neuregulin) (Montero et al., 2000) and APP (amyloid protein precursor). 
The importance of TIMP3 inhibition towards TACE has been demonstrated in the liver 
of TIMP3 deficient mice (Mohammed et al., 2004). This study shows an increased 
amount of soluble TNF-α as a consequence of upregulated TACE activity leading to a 
failure of liver regeneration. 
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Table 2. Summary of ADAM family members and their functions, if known  
 
ADAM Alternative names Proteolytic 
activity 
Function and 
substrate 
ADAM1 PH-30α, Fertillin-α - Sperm–egg binding 
and fusion 
ADAM2 PH-30β, Fertilin-β - Sperm–egg binding 
and fusion 
ADAM3 Cyritestin, tMDC, 
CYRN 
-  
ADAM4 tMDC V -  
ADAM5  tMDC II -  
ADAM6  tMDC IV -  
ADAM7  EAP I, GP-83 -  
ADAM8  MS2 (CD156) + Neutrophil infiltration, 
shedding of CD23 
ADAM9 MDC9, MCMP, 
Meltrin-γ 
 
+ Shedding of HB-EGF, 
TNF-p75 receptor, 
cleavage of  APP, 
digestion of 
fibronectin and gelatin 
ADAM10 MDAM, Kuzbanian + Release of TNF-α, 
digestion of collagen 
IV, gelatin and myelin 
basic protein, cleavage 
of delta, APP, L1, and 
CD44, shedding of 
HB EGF 
ADAM11  MDC -  
ADAM12 Meltrin-α, MCMP, 
MLTN, MLTNA 
+ Muscle formation, 
digestion of IGFBP-3 
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and 5, shedding of 
HB-EGF, digestion of 
collagen IV, gelatin 
and fibronectin 
ADAM13 xMDC13a, x 
ADAM13a 
- Movement of neural 
crest 
ADAM14 ADM-1 -  
ADAM15 Metargidin, 
MDC15, AD56, CR 
II-7 
+ Expression in 
arteriosclerosis, 
digestion of collagen 
IV and gelatin 
ADAM16  xMDC16 -  
ADAM17 TACE, cSVP + Shedding of TNF-α, 
TGF-β, TNF-p75 
receptor, ErbB4, 
TRANCE and HB-
EGF, presence of 
RRKR sequence, 
cleavage of APP, 
Notch, L-selectin and 
CD44 
ADAM18  tMDC III -  
ADAM19  Meltrin-β, FKSG34 + Formation of neuron, 
digestion of 
neuregulin 
ADAM20  + Formation of sperm 
ADAM21  ADAM31 +  
ADAM22  MDC2 -  
ADAM23  MDC3 -  
ADAM24  Testinase-1 - Sperm–egg binding 
Introduction 
 14
and fusion 
ADAM25  Testinase-2 -  
ADAM26  Testinase-3 -  
ADAM27  ADAM18, tMDCIII -  
ADAM28  e-MDC II, MDC-
Lm, MDC-Ls 
+ Digestion of myelin 
basic protein and 
IGFBP-3 
ADAM29  svph 1 -  
ADAM30  svph 4 +  
ADAM32  AJ131563 -  
ADAM33  + Mutation in bronchial 
asthma 
patients, cleavage of 
APP, KL-1 and insulin 
B chain 
ADAM34  Testinase-4 -  
 
(+) and (-)indicates that the ADAM protein does or does not exibit proteolytic activity, 
respectively;  
 
 
1.6.3 TIMP3 and ADAMTS inhibition 
ADAMTSs (a disintegrin and metalloproteinase with thrombospondin motifs) 
form a class of secreted proteinases comprising 19 members (Porter et al., 2005) (Table 
3). Some members of this family of metalloenzymes are bound to the ECM whereas 
others are secreted as soluble molecules. The domain structure of ADAMTS proteins 
from the N- to the C-terminal is as follows: signal peptide (for extracellular export), 
prodomain which confers the latency of the enzyme, a metalloproteinase domain, a 
disintegrin-like domain, a central thrombospondin (TS) type I-like repeat (TS1 and 
TS2), a cysteine-rich domain with ten conserved cysteine residues, a spacer region and 
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various numbers of C-terminal TS repeats (Apte SS, 2004). Functionally, ADAMTS 
proteins are involved in a variety of biological processes. ADAMTS-1 and ADAMTS-8 
have antiangiogentic properties (Vázquez et al., 1999); ADAMTS-1, -4, -5, -8, -9 and -
15 are able to cleave the major cartilage proteoglycan aggrecan; ADAMTS-2, -3 and -
14 are procollagen N-proteinases and process procollagens to collagen by removal of 
their N-terminal propeptide. ADAMTS-1 and ADAMTS-4 are able to cleave versican 
(Sandy et al., 2001; Westling et al., 2004) and brevican (Nakamura et al., 2000; 
Matthews et al., 2000). ADAMTS proteolytic activities are regulated at both the 
transcriptional and the posttranslational level. At the protein level, aggrecanolytic 
activity of the two aggrecanases ADAMTS-4 and ADAMTS-5 are potently inhibited by 
TIMP-3 (Kashiwagi et al., 2001), although it has been shown that the other family 
members can also inhibit ADAMTS4 but with less efficiency (Hashimoto et al., 2001). 
In addition, TIMP3 is able to inhibit the procollagen N-proteinase activity of 
ADAMTS-2 (Wang et al., 2006). Pathologically, some of the ADAMTS family 
members, e.g. ADAMTS4 and ADAMTS5, are involved in osteoarthritis (Malfait et al., 
2002). The major characteristic of this disease is loss of the articular cartilage which is 
mainly composed of aggrecan and collagen type II accounting for 90% of dry weight of 
cartilage. In the excessive catabolism of aggrecan and collagen type II the MMPs are 
also involved (Downs et al., 2001; Otterness et al., 1999). 
 
 
Table 3. A list of known ADAMTS family members and their functions  
 
ADAMTS Alternative names Proteolytic activity Function and 
substrate 
ADAMTS 1  C3-C5, METH1, 
KIAA1346 
+ Binding to heparin, 
presence of RRKR 
sequence, digestion 
of aggrecan and 
versican 
ADAMTS 2  Procollagen N-
proteinase, hPCPNI, 
PCINP 
+ Processing of 
collagen I and II N -
propeptides 
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ADAMTS 3  KIAA 0366 + Processing of 
collagen N-
propeptides 
ADAMTS 4  KIAA0688, 
aggrecanase-1, 
ADMP-1 
+ Digestion of 
aggrecan, brevican 
and versican 
ADAMTS 5  ADAMTS11, 
aggrecanase-2, 
ADMP-2 
+ Digestion of 
aggrecan 
ADAMTS 6    
ADAMTS 7    
ADAMTS 8  METH-2 + Digestion of 
aggrecan, inhibition 
of angiogenesis 
ADAMTS 9  KIAA1312 + Digestion of 
aggrecan 
ADAMTS 10    
ADAMTS 12    
ADAMTS 13  vWFCP, C9orf8 + Cleavage of von 
Willebrand factor 
ADAMTS 14  + Processing of 
collagen N-
propeptides 
ADAMTS 15  + Digestion of 
aggrecan 
ADAMTS 16    
ADAMTS 17  FLJ32769, 
LOC123271 
  
ADAMTS 18  ADAMTS21, 
HGNC:16662 
  
ADAMTS 19    
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ADAMTS 20    
 
(+) indicates that the ADAMTS presents enzymatic activity 
 
 
1.6.4 Antiangiogenic properties of TIMP3 
Formation of the vascular network is a prerequisite for growth and maintenance 
of tissue homeostasis. Formation and remodelling of new blood vessels occurs by three 
distinct processes: vasculogenesis, angiogenesis and arteriogenesis (Buschmann and 
Schaper, 1999). 
Vasculogenesis is a process requiring the differentiation of angioblast (the precursors of 
endothelial cells) into blood islands, which then fuse to form a primitive cardiovascular 
system during embryonic development. Angiogenesis is defined as the formation of 
new capillary blood vessels by sprouting of endothelial cells from pre-existing blood 
vessels. The growth of new blood vessels is a complex network of coordinated 
interactions between several important processes and includes production of proteolytic 
enzymes which degrade the ECM prior to migration of endothelial cells followed by 
endothelial cell differentiation into new vessels and maturation of the vascular wall by 
recruiting mesenchymal cells (Bussolino et al., 1997). Finally, arteriogenesis is the 
rapid proliferation of pre-existing collateral vessels that occurs in ischemic tissue 
(Buschmann and Schaper, 1999). 
Vascular endothelial growth factor (VEGF) is an essential regulator of physiological 
angiogenesis during embryogenesis (Uhlmann, 2006) and is also involved in 
pathological angiogenesis like tumour growth (Ferrara, 1995; Ferrara, 2002), retinal 
disorders (Gariano and Gardner, 2004) and other diseases (Ferrara, 1995). The VEGF 
protein family consists of four isoforms: VEGF121, VEGF165, VEGF189 and VEGF206, 
which arise from alternative exon splicing and bind to 3 different types of tyrosine 
kinase receptors: VEGF receptor 1 (Ftl-1), VEGF receptor 2 (also known as kinase 
domain receptor (KDR) or Flk1) and VEGF receptor 3 (Ferrara et al., 2003). The first 
two receptors are expressed on the cell surface of most blood endothelial cells whereas 
VEGFR-3 is mainly expressed on endothelial cells associated with the lymphatic system 
(Ferrara et. al., 2003). VEGF binds to the extracellular domain of the respective 
receptor and initiates dimerization leading to the activation of an intracellular kinase 
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domain by phosphorylation and initiating a signalling cascade that finally induces 
angiogenesis (Ferrara et al., 2003). 
Initially, it has been shown that TIMP3 protein is able to inhibit angiogenesis (Anand-
Apte et al., 1997) and later that it can inhibit VEGF induced inhibition of angiogenesis 
by blocking VEGF binding to VEGF receptor-2 (Qi et al., 2003). 
 
1.6.5 Proapoptotic activity of TIMP3 
Apoptosis often occurs in tandem with programmed cell death, but there are a 
few distinguishing features. Programmed cell death is characterized mainly by changes 
within the cell at the molecular level resulting from a preexisting death program 
(Saikumar et al., 1999). Apoptosis refers to the morphological features such as cell 
shrinking, chromatin condensation, plasma membrane blebbing or budding and finally 
cell fragmentation into membrane–enclosed structures called “apoptotic bodies” 
containing cytosol, the condensed chromatin and organelles. 
Programmed cell death has an important role during physiological processes of 
multicellular organisms especially during embryogenesis and morphogenesis and also 
plays an important role in the development and maintenance of biological systems. 
These aspects of apoptosis are emphasized by its involvement in many normal but also 
pathological processes. Physiological cell death is a normal process which occurs 
constantly, but it must be balanced with cellular proliferation to maintain the proper 
homeostasis of a pluricellular organism. Distinct from apoptosis, unphysiological cell 
death –termed necrosis- may occur in response to chemical and physical injuries and is 
characterized by cell swelling which leads to membrane disruption. Thus, the cell 
content is released to the extracellular space and elicits an inflammatory response. 
Dysfunction of the apoptotic program can be involved in several diseases such as 
cancer, autoimmune disorder, neurodegenerative diseases (Fadeel et al., 1999). 
TIMP3 induction of cell death has been shown in rat vascular smooth muscle cell 
(Baker et al., 1998). Overexpression of TIMP3 in melanoma cell lines (Ahonen et al., 
1998), HeLa and HT1080 (Baker et al., 1999) promotes apoptosis. Cell death due to 
TIMP3 was demonstrated not only in cancer cells but also in primary porcine 
chondrocytes (Gendron et al., 2003). The proapoptotic activity of TIMP3 was mapped 
to its N-teminus (Bond et al., 2000) and seems to depend on its MMP inhibitory 
activity. 
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1.6.6 TIMP3 as a tumour suppressor gene 
DNA modifications (e.g. DNA methylation) that do not involve changes in the 
underlying DNA sequence of the organism (epigenetics) are the most common covalent 
modifications in the human genome. Their importance has been demonstrated in X 
chromosome inactivation, progress of carcinogenesis and for the developmental control 
of gene expression. In this regard, DNA methylation is directly connected to gene 
silencing through chromatin-remodelling complexes (Robertson & Wolffe, 2000). 
TIMP3 as a tumour suppressor gene is involved in tumour progression by 
hypermethylation of its promoter which, in turn, correlates with TIMP3 gene 
inactivation (loss of protein expression). It has been shown that TIMP3 is involved in a 
variety of tumour invasion/metastatic processes, e.g. in kidney (Bachman et al., 1999), 
pancreatic endocrine tumours (Wild et al., 2003), gastric cancer (Kang et al., 2000), and 
glioblastomas (Nakamura et al., 2005). A possible mechanism of TIMP3 as a tumour 
suppressor gene is suggested by the correlation of TIMP3 expression with the 
invasiveness of glioblastoma. This type of tumour metastasis is associated with the 
cleavage of the extracellular matrix hyaluronan-binding protein brevican (or brain-
enriched hyaluronan binding (BEHAB)) whereas in the non-invasive tumour the protein 
is not cleaved or is not expressed (Zhang et al., 1998; Nutt et al., 2001). The enzyme 
responsible for the cleavage of the brevican was identified to be ADAMTS4 (Matthews 
et al., 2000) and therefore inactivation of TIMP3 might lead to the upregulation of 
ADAMTS4 mediated cleavage of brevican in glioblastomas. 
 
1.7 Aims of the present study 
The main goal of the present study was to elucidate TIMP3 function and its 
possible pathomechanism in Sorsby fundus dystrophy by analyzing two available 
mouse models: TIMP3 knock-out and S156C-TIMP3 knock-in. In the dissection of 
molecular mechanisms underlying the SFD condition an important question was 
whether the free cysteine mutation in TIMP3 could lead to a gain-of-function or 
alternatively a loss-of-function. In this context, it is important to identify the primary 
molecular event that initiates SFD pathogenesis. Towards this goal, the known 
biological functions of TIMP3 were analysed both in vivo by using the mouse models 
and in vitro with recombinant proteins. The inhibitory activity of the S156C mutant 
TIMP3 versus wildtype (WT) TIMP3 towards ADAMTS4, ADAMTS5, TACE and 
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MMPs was analysed in parallel with the remaining TIMP family members to assess the 
redundancy in the functions of these proteins. 
Another objective of the project was to identify new binding partners in an effort to gain 
further insight into disease mechanism. In this context, the binding of TIMP3 to several 
types of collagens was investigated. One of the characteristics of SFD is that the mutant 
protein accumulates in the eyes of the affected patients. Therefore, quantification of the 
S156C mutant TIMP3 in the ECM was determined together with its rate of turnover. 
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2.  Materials and Methods 
 
2.1 Molecular biology methods 
 
2.1.1 Mammalian cell culture and cryopreservation of cells 
Mammalian cell lines were cultivated in different media depending on the cell 
type. HEK-293 EBNA (Human Embryonic Kidney 293, Epstein-Barr virus nuclear 
antigen-1) were maintained in DMEM high glucose with 10 % FBS (Foetal bovine 
serum), Penicillin 100 Units/ml / Streptomycin 100 µg/ml and 500 µg/ml G418 sulfate 
(Geneticin). COS7 and the fibroblasts derived from the TIMP3 knock-out and the 
S156C-TIMP3 knock-in mice were grown in DMEM high glucose with 10 % FBS and 
Penicillin/Streptomycin. Chondrocytes were grown in DMEM/F12, 10% FBS and 
Penicillin/Streptomycin. All cells were grown at 37°C in 5% CO2 atmosphere. For 
propagation of the cells a confluent 10 cm dish was washed with sterile PBS and then 
incubated with 2 ml of trypsin solution (0.05% in PBS) at 37°C for a few minutes 
depending on cell adherence. After cell detachment, the suspension was added to 8 ml 
of culture medium to inactivate the trypsin and centrifuged for 3 min at 1500 rpm. The 
cell pellet was resuspended in 2 ml of medium and cells plated at the density required 
by the experiment. For long term storage, the cell pellet was resuspended in the growing 
medium supplemented with 10% DMSO and the tube was placed in a cryo freezing 
container in the -80°C freezer which allows freezing of the cells with -1°C/min rate of 
cooling. 
 
2.1.2 Culture and conservation of E. coli strains 
A single colony from freshly transformed E. coli was inoculated in 4 ml LB 
medium (Bacto Tryptone 10 g/l, Bacto Yeast Extract 5 g/l, NaCl 5 g/l, pH 7.5) with the 
corresponding selective antibiotic determined by the plasmid and shaken overnight at 37 
°C at 200 rpm. Alternatively, 50 ml of LB medium was inoculated with one colony. 
After overnight growth, 1 L of LB medium was inoculated with this stationary culture 
for protein expression. 
For E. coli cell preservation, a freshly transformed colony was picked and a 5 ml 
preculture was inoculated and grown overnight at 37°C. From the stationary E. coli 
culture an aliquot was taken and mixed with glycerol to a final concentration of 20% 
and stored at -80°C. 
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2.1.3 Preparation and transformation of E. coli competent cells 
 
2.1.3.1 Preparation of bacterial competent cells 
One single colony was inoculated in 5 ml LB medium and grown overnight at 37 
°C. Next day, 500 ml of LB medium was inoculated with the overnight culture and 
grown until OD600 reached 0.8. The cells were harvested by centrifugation at 4000 rpm 
for 15 min at 4°C and subsequently washed with 30 mM potassium acetate, 50 mM 
MnCl2, 100 mM CaCl2 and 15% glycerol, pH 7.0 and incubated on ice for 15 min. After 
centrifugation, the cells were resuspended in 8 ml of 10 mM MOPS, 75 mM CaCl2, 10 
mM KCl, 15 % glycerol, pH 7.0, aliquoted and stored at -80°C. 
 
2.1.3.2 Transformation of competent cells with plasmid DNA 
E. coli competent cells (200 µl) were incubated with 10 µl of ligation mixture 
(or 1 µl of plasmid DNA) on ice for 20 min. The cells were heated at 42°C for 45 
seconds and then 500 µl of SOC medium was added and the cells incubated for 20 
minutes at  37°C. Finally, 100 µl of the transformed cells were plated on a LB agar plate 
with the appropriate antibiotic and incubated overnight at 37°C. 
 
2.1.4 RNA isolation from primary cell culture 
Total RNA was isolated from primary fibroblasts and chondrocytes using the 
Qiagen RNeasy kit according to the manufacturer’s instructions. Briefly, confluent cells 
grown in a monolayer were washed with sterile PBS and detached using trypsin. The 
cell pellet was resuspended in the provided lysis buffer and disrupted by freeze/thaw 
steps. The extract was applied to a spin column and after several washing steps total 
RNA was eluted with 50 µl RNase free water and stored at -80°C. 
 
2.1.5 Plasmid DNA isolation from E. coli 
Analytical scale. To analyse transformed clones for the presence of a specific 
plasmid, to confirm the mutation after site directed mutagenesis or for DNA 
sequencing, the analytical preparation of the plasmid DNA was performed. Plasmid 
DNA was isolated from 5 ml of overnight bacterial culture using a kit from Macherey-
Nagel. Typically, DNA was eluted in 50 µl of buffer. 
Preparative scale. In order to obtain higher amounts of DNA, necessary for 
mammalian cells transfection, plasmid DNA was isolated from 100 ml overnight 
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bacterial culture using the midiprep kit from Macherey-Nagel. DNA was resuspended in 
100 µl of ddH2O and the concentration measured with a NanoDrop ND-1000 
Spectrophotometer. 
 
2.1.6 Gel electrophoresis and DNA purification 
Separation of double stranded DNA was performed by using horizontal agarose 
gel electrophoresis. 
 
2.1.6.1 Analytical agarose gel electrophoresis 
Analytical agarose gel electrophoresis was carried out to analyse PCR fragments 
or the presence of insert after restriction digest. For analytical gel electrophoresis, 100 
ml of 1 to 2 % (w/v) agarose gel (depending on the size of the fragments) was prepared 
in TBE (89 mM Tris/HCl, 89 mM borate acid, 2 mM EDTA, pH 8.3) buffer with 
ethidium bromide. Normally, 5 µl of DNA fragment mixed with 1 µl of 5x PAA loading 
buffer (95% formamide, 5 mM NaOH, 0.1% Bromphenol blue, 0.1% xylene cyanole) 
was applied to each lane. DNA was visualised under UV light after electophoresis.  
 
2.1.6.2 Preparative agarose gel electrophoresis 
Cloning of PCR fragments or subcloning of DNA fragments after restriction 
digest was performed by preparative agarose gel electrophoresis. 100 ml of 1 to 2 % 
(w/v) agarose gel in TBE buffer with ethidium bromide was prepared. The 
electrophoresis was performed at 120 V for approximately 25 min. DNA fragments 
were visualized under UV light and agarose gel containing the correct size DNA 
fragment was excised with a clean scalpel. In the next step, DNA was extracted from 
the gel using a kit from Macherey-Nagel following the manufacturer’s instruction. 
Finally, the DNA was eluted with 20 µl of the supplied buffer. 5µl of the eluted DNA 
was loaded on an analytical gel to check for the recovery and purity of DNA. 
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2.1.7 In vitro modification of DNA 
 
2.1.7.1 Site directed mutagenesis 
Site directed mutagenesis was carried out to introduce point mutations or 
insertions/deletions in a given gene. For this purpose, a primer pair was designed that 
contained the mutated codon or the insertion/deletion. Templates to be modified by site 
directed mutagenesis were present in pGEM vector and subsequently subcloned in the 
desired vector. 
The mutagenesis reaction was performed in a final volume of 25 µl with the following 
composition: 15.8 µl H20, 2.5 µl 10x Pfu buffer 0.6 µl forward primer (10 µM), 0.6 µl 
reverse primer (10 µM), 2 µl dNTPs (1.25 mM of dATP, dCTP, dGTP and dTTP), 2.5 
µl plasmid (200 ng of template) and 1 µl of Pfu ultra high fidelity polymerase. All 
components were pipetted on ice for a hot start PCR reaction. The PCR program used 
was 95°C for 30 sec, annealing 55°C for 60 sec, extension at 68°C for 5 min. After the 
PCR reaction, the methylated DNA (template) was digested by incubating the mixture 
with 1 µl DpnI plus 2.5 µl of 10x NEB4 buffer for 3 hours at 37°C. 10 µl of the digested 
product was transformed into E. coli XL 1 blue competent cells and another 5 µl was 
used for analytical gel electrophoresis. Next day the plasmid DNA was prepared from a 
few picked colonies, then sequenced (and/or restriction digest) to detect the mutation or 
insertion/deletion.  
 
2.1.7.2 Dephosphorylation of linearized plasmid DNA  
In order to subclone a gene using a single restriction enzyme, the digested vector 
was dephosphorylated to avoid the religation of the empty vector backbone. Therefore, 
after a preparative digestion of the vector, the mixture was incubated with 1 µl of 
Antarctic phosphatase at 37°C for 1 hour to remove 5’ phosphate groups from the DNA 
strand. The enzyme was finally inactivated by heating at 65°C for 5 min.  
 
2.1.7.3 Filling in DNA sticky end 
To fill the 5’ overhangs of a DNA fragment after restriction digest to generate a 
blunt end, the large fragment of Klenow DNA polymerase I was used. In a final volume 
of 20 µl the following components were added: 500 ng of restriction digested DNA 
fragment, 2 µl 10x NEB2 buffer, dNTPs to a final concentration of 33 µM, 0.2 µl large 
fragment of Klenow DNA polymerase I (10 u) and 7 µl H2O. The reaction mixture was 
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incubated at 25°C for 15 min and then the enzyme was heat inactivated at 75°C for 20 
min. Finally, 2 µl of 10x ligation buffer and 2 µl T4 DNA ligation was added and 
incubated overnight at 16°C. 
 
2.1.7.4 Polymerase chain reaction (PCR) 
 The polymerase chain reaction (PCR; Saiki et al., 1988) was employed for the 
specific amplification of a gene of interest, site directed mutagenesis or DNA 
sequencing. In principle, in a regular PCR a primer pair is used one of which anneals at 
the 3’ end and the other which anneals at the 5’ end with at least 18 bases hybridising 
specifically to the template. If required, the primers contain at the 5’-end and at 3’ -end 
restriction sites for cloning in a vector. To achieve the amplification of the desired gene, 
thermostable Pfu polymerase (Lundberg et al., 1991) and/or Taq polymerase was used. 
The Pfu DNA polymerase is a proofreading enzyme containing a 3’-to-5’ exonuclease 
activity so that incorrectly incorporated nucleotides are excised. 
Standard PCR reactions were performed in a final volume of 25 µl containing the 
following components: 20-500 ng of DNA template, 10 pmol of each primers, 0.2 µl of 
Pfu and/or Taq DNA polymerase (in-house made), dNTPs and 1x PCR buffer (50 mM 
KCl, 10 mM Tris/HCl, pH 8.3, 1 mM MgCl2) with hot start reaction. The PCR 
amplification of a gene was performed in three steps: first the template DNA was 
denatured by heating it at 94°C for 3-4 min, followed by annealing of the primers to the 
DNA at 52°C to 64°C depending on their melting temperature and the third step, 
elongation of the DNA at 72°C for 1 min per kilobase. Generally, for amplification of a 
gene 25 cycles were performed. 
 
2.1.7.5 First-strand cDNA synthesis 
In order to clone a gene or to quantify it by different methods it is necessary to 
reverse transcribe the RNA to obtain the template cDNA. The elongation reaction was 
performed in a final volume of 20 µl using Superscript II reverse transcriptase (RT) 
(Invitrogen, Karlsruhe, Germany). 1 µg of total RNA together with 1µl oligo dT (500 
µg/ml), 1 µl dNTPs (10 mM of dATP, dGTP, dCTP, dTTP), RNase free water and 
heated to 72°C for 3 min followed by quick chill on ice. Next, 4 µl of 5x first strand 
buffer (250 mM Tris/HCl pH 8.3, 30 mM MgCl2, 375 mM KCl), 2 µl 0.1 M DDT was 
added to the reaction buffer and incubated for 2 min at 42°C. In the end, 0.5 µl of 
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Superscript II was pipetted into the reaction and further incubated for 50 min at 42°C. 
Finally, the enzyme was heat inactivated at 72°C for 15 min. 
 
2.1.7.6 Double stranded DNA cleavage with restriction endonucleases 
For the restriction analysis of plasmid DNA and preparation of DNA fragments, 
restriction digestion was made with the corresponding endonucleases. The reaction 
takes place in a buffer which was supplied by the suppliers. In the case of digestion with 
two different enzymes the buffer was chosen such that both enzymes have the highest 
activity. 
Analytical restriction digestion was carried out in a final volume of 10 µl using 5U of 
the endonuclease, 1 µg of DNA for 60 min at the temperature required for the enzyme. 
For preparative restriction digest, 1 to 10 µg of plasmid DNA was incubated with 20U 
of endonuclease in a final volume of 30 µl. In the case of cloning of PCR fragments, the 
DNA was digested in the same way as for preparative DNA cleavage. For further 
manipulation, digested DNA was separated on a preparative agarose gel or 
phenol/chloroform extracted. 
 
2.1.7.7 Ligation of DNA fragments 
To clone a DNA fragment in a defined vector, the restriction endonuclease 
cleaved DNA fragment was linked covalently via phosphodiester bonds using T4 DNA 
ligase. A typical ligation reaction was performed in a final volume of 10 µl containing: 
1 µl 10x ligation buffer, 1 µl T4 DNA ligase (400 u), vector backbone : insert fragment 
in a ratio of 1:3 and H2O up to 10 µl. The mixture was incubated overnight at 16°C 
followed by transformation of the ligation product into competent bacteria. As a control, 
another ligation reaction was performed containing only the linearized vector. 
 
2.1.7.8 Double stranded DNA sequencing 
 DNA sequencing was carried out on a 3130x/Genetic Analyzer using the 
BigDye Terminator Cycle Sequencing Ready Reaction Kit. This is based on a modified 
Taq DNA polymerase (AmpliTaq; Tabor & Richardson, 1995) that is able to 
incorporate a chain-terminating dideoxynucleotide (ddATP, ddCTP, ddGTP, ddTTP) 
into DNA labelled with different dichlororhodamine dyes (Rosenblum et al., 1997). In 
the PCR reaction the nascent chain is interrupted and results in PCR fragments of 
different sizes, ending with a terminator base labelled with the corresponding 
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fluorophor. During capillary-electrophoresis the PCR fragments are separated on a 
special polymer (Performance Optimized Polymer 6, POP-6) according to size. The 
florescent signal is detected with a CCD (Charge-Coupled Device) camera and recorded 
as a digital signal. 
A standard cycle sequencing reaction is performed in a final volume of 10 µl and has 
the following components: 0.3 µl of BigDye ready reaction mix, 1 µl of one primer 
(either forward or reverse), ddH2O and the template DNA. This can be plasmid DNA 
(often further purified by phenol/chloroform extraction before adding it to the reaction), 
a PCR fragment obtained from colony PCR or amplified from plasmid DNA. In the 
latter case, prior to starting the amplification reaction, the PCR fragments were treated 
with shrimp alkaline phosphatase (dephosphorylates remaining dNTPs) and 
exonuclease I (degrades single-stranded DNA/PCR primers). The incorporation of the 
fluorescently labelled dNTPs takes place in 29 cycles according to the PCR sequencing 
program: 96°C, 30 s; 56°C, 15 s; 60°C, 2 min. The resulting PCR product is precipitated 
by adding 1 µl 3 M Na acetate pH 4.6, 2 µl 125 mM EDTA pH 8.0 and 50 µl ethanol 
(p.a.) mixed vigorously and incubated 15 min at room temperature. After pelleting the 
DNA by centrifugation, it is washed with 70 µl of 70% ethanol and dried at room 
temperature. Finally, the DNA pellet is resuspended in 10 µl HiDi –formamide, 
followed by loading into the sequencer.  
 
2.1.7.9 Phenol/chloroform extraction and ethanol precipitation 
To obtain high quality DNA preparations, phenol/chloroform extractions were 
performed to remove contaminating E. coli proteins. 
 
Phenol/chloroform extraction 
After preparation of plasmid DNA (see section 2.1.5), samples were extracted 
with phenol/chloroform by adding 10 µl of 3 M sodium acetate pH 4.8 and 100 µl 
phenol/chloroform/isoamylalcohol (with the ratio of 25:24:1) and mixed well. The 
samples were centrifuged for 5 min at 14000 rpm, 4°C to separate the aqueous (upper) 
and organic (lower) phases. The upper phase was transferred to a new tube containing 
chloroform/isoamylalcohol (24:1) and reextracted. 
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Ethanol precipitation 
Remaining trace amounts of phenol from the extraction were removed by 
ethanol precipitation. For this, the aqueous phase was mixed with 250 µl of cold ethanol 
(p.a.) and incubated for at least 1 hour at -20°C. After centrifugation (30 min, 14000 
rpm, 4°C) the supernatant was discarded and the pellet was washed with 250 µl 70% 
ethanol. After further centrifugation for 10 min, the supernatant was removed and the 
pellet dried at room temperature. Finally, the precipitated DNA was resuspended in 100 
µl of sterile water and stored at -20°C. 
 
2.1.8 Production of recombinant proteins in E. coli 
 
2.1.8.1 Protein expression in inclusion bodies 
For the production of recombinant proteins or fusion proteins in E. coli as 
inclusion bodies the vectors pET21 or pGEX4T3 were used. 50 ml of LB 
medium/ampicillin was inoculated with a freshly transformed colony of BL21 (DE3) 
strain and incubated overnight at 37°C, 200 rpm. Next day, the stationary grown culture 
was added to 1 L of fresh LB medium and the cells were grown until an OD600 of ~1. 
Protein expression was induced by adding IPTG to a final concentration of 1 mM and 
protein production continued overnight at 30°C. For the isolation of the inclusion 
bodies, the induced culture was centrifuged 15 min at 4°C and the cell pellet 
resuspended in 10 ml of 50 mM Tris/HCl pH 8.0, 100 mM NaCl and 1 mM EDTA. To 
this mixture lysozyme and MgCl2 was added to a final concentration of 1.5 mg/ml and 5 
mM, respectively and incubated for 30 min on ice. To lyse the cells, sonification was 
performed 3 times for 3 min each time with a 3 min interval. Since the viscosity of the 
solution was high, Dnase I (20U) was added to the suspension and incubated for 30 min 
at room temperature. The suspension was then centrifuged at 12000 rpm for 15 min. 
The isolated inclusion bodies were denatured by resuspending the pellet in 25 ml of 50 
mM Tris/HCl pH 8.0, 6 M guanidine hydrochloride, 10 mM β-mercaptoethanol and 
mixing it overnight at room temperature. Next day, the suspension was centrifuged 15 
min at 12000 rpm to remove insoluble material. Denatured recombinant proteins were 
handled in two different ways: TIMP1, TIMP2, TIMP4, N-TIMP3, C-TIMP3 were used 
in this form for refolding whereas full length WT-TIMP3, S156C-TIMP3, MMP13 and 
the TACE catalytic domain were directly applied to a Ni-NTA column for purification. 
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For the expression of proteins fused to GST, 10 ml of preculture was inoculated with 
one freshly transformed colony and incubated overnight by shaking at 200 rpm, 37°C. 
Next day, 500 ml of LB/Amp was added to the overnight culture and further incubated 
until OD600 reached ~1. Protein production was induced overnight by adding IPTG to a 
final concentration of 0.1 mM. The cells were pelleted at 5000 rpm for 15 min, 
resuspended in 5 ml cold PBS supplemented with lysozyme 1 mg/ml and incubated on 
ice for 1 hour. The suspension was sonicated for 1 minute on ice, then for a further 4 
minutes to disrupt the cells. The suspension was centrifuged for 15 min at 12000 rpm 
and the soluble fraction was saved for further purification.   
In parallel, to prepare whole cell extract for the visualization of the proteins, 1 ml of the 
bacterial culture was centrifuged and the cell pellet was resuspended in 100 µl of SDS 
loading buffer. After centrifugation of the lysate, 25µl of the soluble fraction was 
applied to an SDS-PAGE gel together with samples from each purification step to check 
for the presence and purity of the protein. 
 
2.1.8.2 Recombinant protein refolding 
After denaturation, proteins were refolded in 100 ml of refolding buffer. 1 ml of 
denatured protein solution was added dropwise to 100 ml of refolding buffer with the 
following composition: 100 mM Tris/HCl pH 8.5, 1 M arginine, 100 mM NaCl, 5 mM 
reduced glutathione, 0.5 mM oxidized glutathione and stirred for 2 days at 4°C. In the 
case of TIMP1, TIMP2, TIMP4, N-TIMP3 and C-TIMP3 the refolded protein solution 
was dialyzed against 50 mM NaH2PO4, 300 mM NaCl, pH 8.0 (dilution factor 100) 
before Ni-NTA chromatography. For full length WT-TIMP3 and S156C-TIMP3 
(obtained after Ni-NTA purification), the recombinant refolded proteins were kept and 
used in the bioactivity assays in this buffer. 
 
2.1.9 Recombinant protein expression in mammalian cells 
Unlike bacterial expression systems – where the overexpressed mammalian 
protein most often is found unfolded in inclusion bodies and needs to be refolded – 
expression of proteins in mammalian cells has the advantage of natural environment 
allowing proper protein folding.  
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2.1.9.1 Transient transfections 
Various cell lines (HEK-293 EBNA, COS-7) were grown to approximately 80% 
confluency and transfected using calcium phosphate method (Chen et al., 1987). 
Typically, for one 10 cm dish, 10 µg of plasmid DNA was pipetted in 370 µl (final 
volume) of water and, 123 µl of 1 M CaCl2 and 495 µl 2x BBS (50 mM BES [N,N-
Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid], 280 mM NaCl, 1.4 mM Na2HPO4, 
pH 6.95) by voretexing and incubated at room temperature for 30 min. The calcium-
phosphate/DNA precipitate was added dropwise to the cells such that the whole plate 
was covered. Next day, the medium was changed as the solution used for transfection is 
toxic to the cells. Recombinant proteins were harvested after one to three days. 
 
2.1.9.2 Stable transfections 
To obtain higher amounts of protein, stable transfectants were generated. 
Plasmid DNA prepared by using a commercially available kit was further purified by 
phenol-chloroform extraction and ethanol precipitation. The cells were transfected using 
the calcium-phosphate method as described for transient transfections. The medium was 
changed next day for regular medium and the cells were incubated for one more day for 
recovery. 36 hours posttransfection a selection medium was applied containing 250 
µg/ml hygromycin B. The medium was changed every day for approximately 3 weeks 
until colonies resistant to hygromycin B started to appear. The colonies were trypsinized 
and plated on a new cell culture dish. The cells were maintained in DMEM with 50 
µg/ml hygromycin. On a control plate containing non-transfected cells, the cells died 
within 10 days of the start of selection. 
 
2.2 Biochemichal methods 
 
2.2.1 Protein purification 
Enzyme-inhibitor kinetic analysis requires that the recombinant proteins are 
homogenous and in a highly pure state. Purification of recombinant proteins can be 
achieved by attaching an affinity tag to the protein of interest and performing the 
corresponding chromatography. 
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2.2.1.1 Immobilized metal affinity chromatography (IMAC) 
This method is based on the principle of interaction of an oligohistidine tag with 
a bidentate or tridentate chelating agent. For isolation of recombinant his-tagged 
proteins, a column was used with 5 ml bed volume (Ni-NTA agarose) and a peristaltic 
pump. First, the column was regenerated with 50 mM EDTA, 300 mM NaCl 
(regeneration buffer) followed by washing the column with water. After recharging the 
column with 50 mM NiSO4 and washing with water, the column was again loaded with 
IMAC buffer (50 mM Na H2PO4, 300 mM NaCl pH 8.0). Next, recombinant protein 
was applied to the column and washed with IMAC buffer. Elution of protein bound to 
the column was achieved using a 40 ml linear concentration gradient from 0 to 250 mM 
of imidazole in IMAC buffer at a flow rate of 1 ml/min, and 2 ml fractions were 
collected. After elution, the column was washed with regeneration buffer to remove all 
proteins which might have remained after competitive elution to allow the column to be 
reused for purification of other proteins. The collected fractions of eluted recombinant 
protein were analysed on a SDS-PAGE gel to check for purity. The fractions with the 
highest purity and yeild of protein were pooled and concentrated with an Amicon 
concentrator. Alternatively, proteins were used directly for refolding after purification. 
Recombinant proteins were stored in aliquots at -20°C. 
 
2.2.1.2 Glutathione-S-transferase (GST) chromatography 
The soluble fraction from disrupted cells expressing GST fusion proteins was 
used for purification via glutathione beads. Prior to the purification, 250 µl of 
glutathione beads were washed 3 times with 1 ml cold PBS. After that, the soluble 
fraction was added to the washed beads and incubated by rotation at 4°C for 1 hour. The 
beads were collected by centrifugation (5 min, 500 rpm) followed by washing 3 times 
with 1 ml cold PBS. The GST fusion protein was eluted with 250 µl of 35 mM of 
reduced glutathione prepared in 50 mM Tris/HCl pH 8.8. From the collected fractions, 
the recombinant fusion proteins were checked on a SDS-PAGE for purity and/or 
degradation. 
 
2.2.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated according to their molecular mass by discontinuous 
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970). The 
percentage of acrylamide in the gel for separation of protein depends on the size of the 
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protein. The higher the molecular mass the lower is the percentage of the gel used and 
vice-versa. For separation of TIMPs, a 15% SDS gel was regularly used. To prepare 
SDS gels with different percentages the following components were mixed: 
 
 Lower Gel Percentage (vol in mls)  Upper gel 
stock solution  5% 6% 7% 8% 9% 10% 11% 12% 13% 14% 15%  
1 M Tris 8.8  3.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75 
0.62 ml pH 
6.8 
10% SDS  0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.05 
40% 
Acrylamide  
1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00 3.25 3.50 3.75 0.5 
H2O  4.95 4.70 4.45 4.20 3.95 3.70 3.45 3.20 2.95 2.70 2.45 3.8 
TEMED(µl) 30 30 30 30 30 30 30 30 30 30 30 30 
APS 10%(µl) 30 30 30 30 30 30 30 30 30 30 30 30 
 
After assembling the plates and mixing the SDS gel components the gel was poured 
between two glass plates and then covered with 1 ml of water. Polymerization was 
allowed for 20 min and thereafter the upper gel was added with inclusion of a comb. In 
the meantime, 25-35 µl of protein sample with the corresponding loading buffer was 
denatured by heating to 95°C for 5 min and then loaded on the gel. Electrophoresis was 
performed at 120 V and run until the bromphenol blue reached the bottom of the gel. 
The gel was either used for transfer of the proteins to a membrane for western blotting 
or stained with Coomassie brilliant blue for 20 min followed by destaining. 
 
2.2.3 Zymography 
Zymography is a method for analysing the gelatinolytic activity of MMP2 
(gelatinase A) and MMP9 (gelatinase B). In principle, the method is similar to SDS-
PAGE except for incorporation of the enzymes substrate – gelatin – in the gel. A 10% 
SDS gel was prepared with the addition of 10 mg/ml gelatin. To do this, 40 mg of 
gelatine was dissolved in 3 ml water and 3.75 ml 1 M Tris/HCl pH 8.8 by heating in a 
microwave for up to 1 min. After cooling the gelatine solution to approximately 50°C, 
the rest of the components were added: 2.5 ml acrylamide, 100 µl 10% SDS, 30 µl of 
10% APS (ammonium persulfate) and 30 µl TEMED (N,N,N′,N′-
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Tetramethylethylenediamine). After polymerization, the upper part was made as for 
normal SDS-PAGE. To prepare samples for testing MMP activity, 30 µl of a solution 
containing the enzymes was mixed with SDS loading buffer without reducing agent (β-
mercaptoethanol or DDT) and incubated for 10 min at room temperature. Thereafter, 
the samples were loaded on the gel and electrophoresed at 120 V, 25 mA on ice until 
the bromphenol blue reached the bottom of the gel. Then, after electrophoresis the gel 
was incubated 3 times for 30 min in 50 mM Tris/HCl pH 7.5, 5 mM CaCl2 and 2.5 % 
triton X-100. Triton will replace the SDS from the gel thus promoting the renaturation 
of the MMPs. In the next step, the gel was incubated in 50 mM Tris/HCl pH 7.5, 5 mM 
CaCl2 overnight at 37°C to allow the cleavage of the gelatin by MMPs. Finally, the gel 
was stained with Coomassie brilliant blue for 10 min, followed by destaining with a 
solution containing 20 % methanol and 10 % acetic acid. At the corresponding 
molecular mass for migration of the MMPs the gelatin is cleaved and appears as a clear 
band on a blue background.   
 
2.2.4 Reverse zymography 
With this procedure, the inhibitory activity of TIMPs towards MMPs can be 
determined. Typically, for reverse zymogram, a 12.5% gel was prepared; 40 mg of 
gelatin was dissolved in 2 ml water and 3.75 ml 1 M Tris/HCl pH 8.8 by heating it in a 
microwave. After cooling 1 ml of conditioned medium from HT1080 cell line (a 
fibrosarcoma cell which secrets MMPs) was added with the remaining SDS gel 
components: 3.1 ml acrylamide, 100 µl 10% SDS and 30 µl of 10% APS/TEMED. SDS 
loading buffer was added to the samples without reducing agent and incubated for 10 
min at room temperature. The gel was loaded with the respective TIMP protein and 
electrophoresed on ice at 120 V, 25 mA for 1.5 hour followed by staining with 
Coomassie brilliant blue for 10 min. Finally, the SDS gel was destained until the bands 
were visible. 
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2.2.5 Measurement of protein concentration 
 
2.2.5.1 Estimation of protein concentration at 280 nm absorption 
In order to measure the concentration of a purified protein in solution for kinetic 
measurements, Lambert-Beer law was employed:  
A = ε·c·d 
 
where A = absorbance at 280 nm; ε = molar extinction coefficient; d = pathlength in 
cm; c = molar concentration. Calculation of the extinction coefficient was made using 
software available on the internet (http://www.biomol.net/tools-protein-extinction-
coefficient.php). The extinction coefficient is given by the sum of the absorption of the 
aromatic residues (tryptophan and tyrosine) in the polypeptide chain of a protein (Gill & 
von Hippel, 1989). 
In the present study the extinction coefficients of the following proteins were used: 
 
Protein  ε280 [M-1cm-1] 
TIMP1 27555 
TIMP2 33180 
TIMP3 46590 
TIMP4 40630 
N-TIMP3 19285 
C-TIMP3 27305 
MMP13 83958 
TACE catalytic domain 32235 
 
2.2.5.2 Estimation of protein concentration by Lowry assay 
The Lowry assay (Lowry, 1951) is a colorimetric method that provides an 
estimation of the total protein concentration in a cell extract or a mixture of proteins 
(unpurified proteins). It was performed using the BioRad DC kit according to the 
manufacturer’s recommendations. Briefly, for a sample of 20 µl, 100 µl of solution A’ 
(composed of 200 µl reagent A plus 4 µl reagent S) was added and mixed with 800 µl 
reagent B followed by incubation for 15 min at room temperature. In the meantime, a 
serial dilution of BSA was prepared in the concentration range of: 0.2 mg/ml, 0.4 
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mg/ml, 0.8 mg/ml, 1.6 mg/ml, 3.2 mg/ml. The absorbance of the colorimetric reaction 
was measured at 750 nm. The absorbance values thus obtained were plotted against the 
corresponding concentration creating the calibration curve. 
 
2.2.6 ECM protein preparation 
In the cell culture system TIMP3 is localized bound to the ECM of the cell. To 
remove the proteins from this compartment, the cells were trypsinized and the plates 
were washed 2 times with PBS followed by scraping the ECM proteins with 70 to 100 
µl of SDS loading buffer or 1% PBS Triton X100 and then stored at -20°C. 
 
2.2.7 Preparation of cell extracts 
Cell lysate was made by resuspending the cells from a 10 cm dish in 250 µl cold 
PBS and then adding 250 µl of 2% Triton X-100 in PBS. The mixture was incubated for 
30-60 min on ice with occasional agitation. After this incubation time the cell extract 
was centrifuged 10 min at 13000 rpm to remove the insoluble material, while the 
supernatant was kept for further analysis and stored at -20°C. 
 
2.2.8 Concentration of protein solution 
Secreted proteins from cell culture supernatant or proteins after purification are 
often at low concentrations in large volumes. For analysis (e.g. detection in Western 
blotting, ELISA, SDS-PAGE) it is necessary to concentrate these protein solutions to 
bring the protein concentration to a more optimal level for the assay. The protein 
solution was placed in an Amicon concentrator (reservoir volume 4 ml) with a 
molecular cut-off of at least 10 000 Da less than the size of the protein and then 
centrifuged at 3500 g until the protein solution reached typically 200-250 µl. In some 
instances, the buffer was exchanged by adding 8 ml of the final desired buffer and spun 
again to 200-250 µl final volume. Concentrated protein was transferred to an eppendorf 
tube and then centrifuged at 13000 rpm for 1 min to remove any aggregated protein 
which may have occurred during concentration. The supernatant was saved and the 
protein concentration was measured either by the Lowry method or by absorption at 280 
nm, aliquoted and stored at -20°C. 
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2.2.9 Pull-down assay 
One method to investigate the interaction of two proteins in solution is the so-
called pull-down assay. The assay is based on the presence of a tag fused to one of the 
interacting partners that can be pulled down by specific affinty beads. In this particular 
experiment Ni-NTA (Nickelnitrilotriacetate) beads were used to pull down the complex 
formed between His-tagged TIMP3 and TTR (transthyretin). 300 nM of purified and 
refolded TIMP3 with a hexahistidine tag was mixed with concentrated conditioned 
medium from HEK-293 cells transfected with pCEP4-TTR with a 1D4 tag and rotated 
overnight at 4°C. Next day, 100 µl of washed Ni-NTA beads were added to the protein 
solution and further incubated for 2 hours at 4°C. The beads with the protein complex 
bound via hexahistine tag were washed 3 times and the complex was eluted with 50 mM 
NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0. The eluted protein fraction was 
divided into two equal aliquots and analysed by western blotting for the presence of 
TTR and for TIMP3. 
 
2.3 Immunochemistry methods 
 
2.3.1 Immunoprecipitation of proteins 
By immunoprecipitation an antigen can be specifically bound to an antibody and 
enriched or purified from a complex protein mixture. The protein to be 
immunoprecipitated was prepared from cell extract or ECM and incubated with the 
corresponding antibody (typically around 10 µg) by rotation for 2-4 hours or overnight 
at 4°C. Protein A beads were washed 2 times with 500 µl 0.1% PBS Triton X-100 and 
centrifuged 2 min at 1000 rpm. The washed beads (20-40 µl) were added to the 
antibody-antigen complex and rotated for an additional 2 hours. The antibody-antigen 
complex bound to protein A beads was recovered by centrifugation for 5 min at 1000 
rpm and then washed two times with 0.1% Triton X-100 in PBS. The antigen was eluted 
from the beads in 50 µl SDS loading buffer. Typically, 20 to 25 µl of the elution 
product was analyzed by SDS-PAGE and western blotting and the rest was stored at -
20°C. 
 
2.3.2 Enzyme-Linked Immunosorbent Assay (ELISA) 
The binding activity of an antibody towards its antigen can be analyzed by 
ELISA. In principle, the antigen is immobilized on the surface of a microtiter plate by 
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adsorption. After the application of antibody the complex can be detected by using a 
secondary antibody (specific for mouse or rabbit IgG) conjugated with horse radish 
peroxidase (or another reporter enzyme). The intensity of the chromogenic reaction is 
directly proportional to the amount of antibody bound to the immobilized antigen. 
For ELISA, 96-well microtiter plates were coated with 50 µl of antigen (GST 
fusion proteins or collagens) and incubated overnight at 4°C. Next day the antigen 
solution was discarded and the wells blocked with 200 µl of 3% w/v BSA in PBST 0.1 
per well for 1 hour at room temperature. After washing the wells with PBST 0.1, 50 µl 
of PBST 0.1 was added to each well except for the second and the last rows. The first 
row represents the control which accounts for the background given by unspecific 
binding of the secondary antibody. In the second row 100 µl of antibody (or protein) 
solution was pippeted and from this volume 50 µl was taken and serial dilutions of 1:1 
were made. The plate was then incubated for 1 hour at room temperature. After three 
washing steps with PBST 0.1, the secondary antibody conjugated with horse radish 
peroxidase was added and the plate incubated for 1 hour room temperature. The wells 
were washed with PBST 0.1 before the enzyme substrate (tetramethyl benzidine) was 
added. This produces a blue colour. For end point measurement the enzymatic reaction 
was stopped by adding 1 N HCl and the intensity of the chromogenic reaction was 
measured at 450 nm. The absorption values thus obtained were plotted against the 
concentration of the antibody. 
 
2.3.2.1 Determination of the apparent dissociation constant by ELISA 
For evaluation of the data obtained in a binding assay between a protein and its 
ligand, a simple thermodynamic reaction is used: 
 [P]+[L] [PL] (1) 
The dissociation constant is defined by the following equation: 
 
]LP[
]L[]P[KD ⋅
⋅=  (2) 
Where: [P] is the concentration of free protein; [L] is the concentration of uncomplexed 
ligand and ]LP[ ⋅  is the concentration of the protein-ligand complex. 
Making a few assumptions that: 
 ]LP[]P[]P[ t ⋅+=  (3) 
and 
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 ]LP[]L[]L[ t ⋅+=  (4) 
Where: [P]t is the total amount of protein; [L]t is the total amount of ligand. 
Rearranging equations (3) and (4) gives: 
 ]LP[]P[]P[ t ⋅−=  (5) 
and 
 ]LP[]L[]L[ t ⋅−=   (6) 
In the initial dissociation equation (2) the concentrations of the protein and ligand are 
replaced with the equation (5) and (6) resulting in: 
 
]LP[
])LP[]L([])LP[]P([K ttD ⋅
⋅−⋅⋅−=   (7) 
Assuming that [P]t>> L][P ⋅  and resolving the equation for L][P ⋅  gives: 
 
Dt
tt
K[P]
[L][P]L]P[ +
⋅=⋅   (8) 
 
The measured absorbance values at 450 nm are plotted against the corresponding 
protein concentrations (representing [P]t which was used in the assay). The points 
obtained in the graph are fitted by non-linear least squares regression according to 
equation (8) with KD and [P]t as parameters (Voss & Skerra, 1997). 
 
2.3.2.2 ELISA applied to cells 
In order to study the inhibitory activity of TIMP3 towards 
ADAMTS4/ADAMTS5 a modified ELISA was developed. In this assay the primary 
chondrocytes were plated on a microtiter plate. After growing, the cells were incubated 
with the first antibody (neoepitope) and the secondary antibody conjugated with HRP. 
The intensity of the chromogenic reaction correlates with the activity of enzymes 
inhibited by TIMP3. 
Isolated chondrocytes were plated on an ELISA plate at a density of 1.5x 104 
cells per wells and grown for 7 days changing the medium every second day. Then the 
cells were incubated in serum free medium for 2 days before starting detection of the 
enzymes and their cleavage product. In the case of treatment with recombinant TIMP 
proteins at day 5 the cells were incubated with 100 ng/ml of inhibitors in medium with 
serum for two days and then two additional days in serum free medium, exchanging the 
medium every day with fresh inhibitors. At the end of the growing phase, the cells were 
washed 2 times with PBS and fixed with 4% paraformaldehyde in PBS for 30 min at 
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room temperature. The cells were washed again with PBS (3 times) and then incubated 
with 50 µl of 0.05U of chondroitinase ABC (prepared in 50 mM Tris/HCl, 60 mM 
sodium acetate, 0.01% BSA, pH 8.0) for 2 hours at 37°C. Digestion with chondroitinase 
was necessary to remove the chondroitin sulfate from the aggrecan in order to unmask 
the antibody recognition epitope (this treatment was for detection of ADAMTS neo, 
MMP neo and aggrecan). After blocking with 3% BSA (in PBS containing 0.3% Triton 
X-100) cells were incubated with the first antibody overnight at 4°C. Next day, the 
wells were washed 3 times with PBS and then incubated with the corresponding 
secondary antibody coupled with horse radish peroxidase for 1 hour at room 
temperature. The wells were washed again and incubated with 100 µl of 
tetramethylbenzidine. The enzymatic reaction produced a blue colour which was 
stopped by adding 100 µl of 1 N HCl giving a yellow colour of which intensity was 
measured at 450 nm, using a FLUOstar OPTIMA (BMG Labtech) plate reader. As a 
control a well was processed the same way but omitting the first antibody. The control 
value was subtracted from the sample absorption intensity before plotting the data. 
 
2.3.2.3 Competitive ELISA 
This assay is similar to a regular ELISA except that a competitor is preincubated 
with the ligand. Briefly, increasing concentrations of TIMP3 (27.5 nM to 1760 nM) 
were added to a constant amount of VEFGR2 (20 nM) in a final volume of 50 µl in PBS 
and complexs were allowed to form overnight at room temperature. The wells of a 
microtiter plate were coated with 50 µl of 0.2 µg/ml VEGF solution and incubated 
overnight at 4°C. Next day, the wells were washed with PBS and blocked with 3% BSA 
(w/v in PBS) for 1 hour at RT. The complex formed between TIMP3 and VEGFR2 was 
added to the immobilized VEGF for 2 hours. After washing the wells with PBS, 
polyclonal anti-VEGFR2 antibody (dilution 1:500) was applied for 1 hour. In the next 
step, VEGFR2 bound to its ligand VEGF, was detected by addition of secondary 
antibody coulpled to peroxidase. After 1 hour the substrate of the enzyme - tetramethyl 
benzidine - was added. The enzymatic reaction was stopped by adding 100 µl 1 N HCl. 
The intensity of the yellow reaction product was measured at 450 nm. In the control 
well the complex between TIMP3 and VEGFR2 was omitted to quantify the unspecific 
background (given by the first and the secondary antibodies). The absolute absorbance 
values were calculated by subtracting the background from the sample values and were 
plotted against the concentration of TIMP3. 
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2.3.3 Western blotting 
In western blotting an antibody is used to detect a specific protein in a mixture 
separated by SDS-PAGE. First, the protein mixture is separated on a SDS 
Polyacrylamide gel by electrophoresis then it is electro-transferred to a hydrophobic 
membrane and immuno-detected with the corresponding antibody. 
Proteins were separated by SDS-PAGE as described in section 2.2.2. After 
electrophoresis finished, the gel was soaked in Towbin buffer (25 mM Tris/HCl pH 8.3, 
190 mM glycine, 10% methanol). In the meantime, the hydrophobic membrane 
(Immobilon PVDF, Millipore) was activated in 10 ml of methanol for 5 min and then 
incubated in Towbin buffer. At the same time two whatman filter papers were socked in 
Towbin buffer. For the electro-transfer, the prewetted whatman paper was laid on the 
electro-transfer apparatus followed by the hydrophobic membrane and the SDS gel and 
one whatman filter paper. Electro-transfer took place at 120 mA, 10 V for 1 hour. Next 
the membrane with the transferred protein was blocked with 3% milk or BSA prepared 
in PBS for 1 hour at room temperature or overnight at 4°C. The first monoclonal or 
polyclonal antibody was added at a previously determined dilution for 1 hour. The blot 
was washed three times with 20 ml PBST 0.05, 10 min each time. The secondary 
antibody (anti rabbit or anti mouse) conjugated with horse radish peroxidase was added 
and incubated for 1 hour and then washed again three times with PBST 0.05. Antibody 
bound to antigen was detected by incubating the membrane for 1-2 min with 2 ml of 
ECL reagent composed of: 1 ml SuperSignal West Pico Luminol/enhancer solution and 
1 ml SuperSignal West Pico Stable Peroxide solution (Pierce). X-ray film was exposed 
to the blot, depending on the signal intensity, for 30 seconds up to 30 min to detect the 
signal on the blot. 
 
2.3.4 Immunocytochemistry 
In order to localize/colocalize a protein/two proteins or detect a specific marker 
on primary isolated cells (to identify the marker for a specific cell type) or to determine 
the transfection efficiency, cells are stained with the appropriate primary antibody 
followed by a secondary antibody conjugated with a fluorophor which can be detected 
by using a fluorescence microscope.  
Cells were grown on cover slips then washed two times with PBS and fixed with 4% 
PFA for 30 min at room temperature. After washing, the cells were blocked with 10 % 
goat serum in PBS containing 0.3% Triton X-100 (Triton X-100 helps to permeabilize 
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the cells so that the antibody has access to intracellular proteins), for one hour at room 
temperature. The cover slips were incubated with the first antibody (at various dilutions) 
in 2.5 % goat serum and 0.1% Triton X-100 for 1 hour at room temperature or overnight 
at 4°C. The cover slips were washed 3 times with PBS and then incubated with the 
secondary antibody conjugated with a fluorophor at a dilution of 1:1000 or 1:5000 for 1 
hour. From this stage all other steps were carried out in the in dark due to the light-
sensitivity of the fluorophor. The cells were washed three times and incubated with 
DAPI to stain the nucleus of the cells. Cover slips were mounted onto slides in confocal 
matrix oil. Specific staining was visualized using a fluorescence microscope. 
 
2.4 Biophysical methods 
 
2.4.1 Fluorescence resonance energy transfer (FRET) 
In principle, fluorescence resonance energy transfer (FRET) is the transfer of 
energy from a fluorescent donor excited at a specific wavelength to an acceptor over 
distances as large as 70 Å (Stryer, 1978). In these experiments (TACE and MMPs 
assay), the fluorophor group (7-methoxycoumarin-4-yl) acetyl) is separated from the 
quencher group (N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl) by a short peptide 
containing the cleavable site for TACE or MMP; quenching occurs by resonance energy 
transfer (Knight et al., 1992). 
 
2.4.1.1 Fluorometric TACE assay 
TACE extraction from the liver of gene targeted mice was performed essentially 
as described by Mohammed et al., 2004. Briefly, 200 µg of total liver extract was 
incubated with 1 µM of TACE substrate (MCA-PLAQAV-Dpa-RSSSR-NH2) in TACE 
assay buffer (50 mM Tris/HCl pH 7.5, 150 mM NaCl, 10 mM CaCl2, 0.05% Brij 35). 
Fluorescence was measured after 1 h incubation at 27°C with a FLUOstar OPTIMA 
(BMG Labtech) set at 330 nm excitation and 390 nm emission. For TACE inhibition by 
recombinant proteins, the recombinant catalytic domain of TACE (100 nM) or native 
TACE (50µg) was incubated with increasing concentrations of TIMPs (3 nM to 220 nM 
for recombinant TACE catalytic domain and 25 nM to 1000 nM for native TACE) and 
the complex allowed to form for 3 h at room temperature. 1 µM fluorogenic substrate 
(final concentration) was added to the complx in a 100 µl reaction volume. The 
fluorescence was measured after 2 h incubation at 27°C. 
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2.4.1.2 Fluorometric MMP13 assay 
 Recombinant mouse MMP13 was expressed in inclusion bodies, purified and 
refolded. Prior to performing the fluorometric inhibitory assay, MMP13 was activated 
by incubation with 1 mM of APMA (4-Aminophenylmercuric acetate) at 37°C for 2 h. 
For the concentration dependent inhibition of MMP13, 0.6 nM of activated enzyme was 
mixed with an increasing concentration of recombinant TIMP3 (0 to 3.8 nM). The 
complex formation between MMP13 and TIMP3 was allowed to form for 2 hours at 
room temperature, before 1 µM of MMP13 fluorogenic substrate (MCA-Pro-Cha-Gly-
Nva-His-Ala-Dpa-NH2 [Cha=L-cyclohexylalanine; Dpa=3-(2,4-dinitrophenyl)-L-2,3-
diaminopropionyl; Nva=L-norvaline], Calbiochem) was added to the reaction and 
further incubated for 2 hours at 27°C. Fluorescence was measured with the excitation 
wavelength set at 330 nm and the emission wavelength at 390 nm. 
 
2.5 Cell biology methods 
 
2.5.1 Isolation of primary chondrocytes from mouse ribs 
Tissue was removed from mouse ribs and incubated in 2 mg/ml collagenase in 
DMEM with 10% FBS for 10 min at 37°C, then for 20 min at room temperature to 
remove the remaining tissue. The medium was changed for a fresh solution of 2 mg/ml 
collagenase and incubated overnight in a 37°C incubator. Next day the cell suspension 
was filtered through a mesh (pore size 50 µm) and the cells pelleted for 5 min at 1500 g. 
The cells were resuspended in fresh DMEM with 10% FBS and plated on a 6 cm dish. 
Chondrocytes were grown for 2-4 days and then split into 2x 10 cm dishes. One dish 
was used for conservation of the cells and the other for plating in ELISA wells. 
 
2.5.2 Preparation of liver extract 
Livers from mice were removed, shock frozen in liquid nitrogen and stored at -
80°C. One complete liver was homogenized in 3 ml of extraction buffer (50 mM 
Tris/HCl, 150 mM NaCl, 0.1% SDS, 1% sodium deoxycholate, 1% Nonidet P40, 1% 
Triton X-100, pH 7.4). The solution thus obtained was centrifuged for 15 min, 13000 
rpm at 4°C and the supernatant was aliquoted and stored at -80°C.  
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3. Results 
 
3.1 Production and structural characterization of soluble 
recombinant proteins  
Investigation of TIMP3 biological function and analysis of the pathomechanism 
of SFD required the production of recombinant proteins. Moreover, TIMP3 is an 
enzyme inhibitor and study of inhibitory kinetics requires high purity and reasonable 
amounts of protein. Therefore, TIMP3 and the other necessary recombinant proteins 
were cloned in a bacterial vector, expressed, purified and refolded. 
 
3.1.1 Construction of a bacterial expression vector for the production 
of TIMP-1, -2, -3, -4, MMP13 and TACE-CD 
Although bacterial expression of the recombinant proteins has the disadvantage 
that the proteins are non-functional and deposited in inclusion bodies, it also has the 
advantage that proteins are produced in large amounts and, after refolding, yields are 
still good. On the other hand, it is possible to express proteins in bacteria in a soluble 
form by directing them to the periplasmic space of gram negative bacteria where the 
proper oxido-reducing conditions are present which favour the formation of disulfide 
bonds – necessary for the protein to be biologically active and perform its function. 
However, high numbers of cys residues in a recombinant protein usually leads to a 
drastic drop in the amount expressed in the periplasm, presumably from overloading the 
secretory pathway and folding machinery of the bacteria. Therefore, in the present study 
I chose to express all the recombinant proteins in the cytosol.   
The T7 expression system (Studier et al., 1990) was used for prokaryotic expression of 
recombinant proteins in the commercially available vector pET21 (Novagen). TIMP 
cDNAs were cloned in-frame with a hexahistine tag at the C-terminus to facilitate 
protein purification. The expressed proteins formed inclusion bodies and after 
solubilisation and refolding the proteins were purified by IMAC and further 
characterized for functionality. 
The templates used for cloning of the TIMPs and other recombinant proteins were made 
from cDNA. First strand synthesis was carried out from RNA isolated from WT 
chondrocytes or fibroblasts. The cDNAs were amplified using the following primer 
combinations: TACE_CD_pET_F/ TACE_CD_pET_R (TACE catalytic domain, 
Arg215 to Val477), MMP13_F/ MMP13_R (MMP13, Tyr24 to Cys449), 
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TIMP1_N_F/TIMP1_C_R (full length TIMP1, Cys1 to Arg181); 
TIMP2_N_F/TIMP2_C_R (full length TIMP2, Cys1 to Pro194); 
TIMP3_N_F/TIMP3_C_R (full length TIMP3, Cys1 to Pro188); 
TIMP3_N_F/TIMP3_N_R (N-terminal TIMP3, amino acid Cys1 to Asn121); 
TIMP3_C_F/TIMP3_C_R (C-terminal TIMP3, amino acids Cys122 to Pro188); 
TIMP4_N_F/TIMP4_C_R (full length TIMP4, Cys1 to Arg195). S156C-TIMP3 was 
amplified with the same primers as for WT, and the point mutation was introduced by 
site directed mutagenesis using the primers: F_S156C/B_S156C prior to cloning into 
pET vector. Fragments were amplified with a mixture of Taq and Pfu polymerases (8:1) 
(Pfu polymerase has a proof reading activity and Taq polymerase leaves single A 
overhangs and thus is useful for cloning into pGEM vector) using a touch-down PCR 
protocol. The amplified PCR fragments were ligated in the pET21 vector using NdeI 
and XhoI restriction sites (Fig. 3). 
 
 
1                                             (Timp3_N_F)GCT 
ATGACTCCCTGGCTTGGGCTTGTCGTGCTCCTGAGCTGTTGGAGCCTTGGGCACTGGGGC 
---------|---------|---------|---------|---------|---------| 
TACTGAGGGACCGAACCCGAACAGCACGAGGACTCGACAACCTCGGAACCCGTGACCCCG 
MetThrProTrpLeuGlyLeuValValLeuLeuSerCysTrpSerLeuGlyHisTrpGly 
1                           10                            20 
 
    NdeI 
AGCCATATGTGCACATGCTCTCCCAGCC                             120 
GCGGAAGCGTGCACATGCTCTCCCAGCCATCCCCAGGATGCCTTCTGCAACTCCGACATC 
---------|---------|---------|---------|---------|---------| 
CGCCTTCGCACGTGTACGAGAGGGTCGGTAGGGGTCCTACGGAAGACGTTGAGGCTGTAG 
AlaGluAlaCysThrCysSerProSerHisProGlnAspAlaPheCysAsnSerAspIle 
                            30                            40 
 
121                                                      180 
GTGATCCGGGCCAAAGTGGTGGGAAAGAAGCTGGTGAAGGAGGGGCCCTTTGGCACTCTG 
---------|---------|---------|---------|---------|---------| 
CACTAGGCCCGGTTTCACCACCCTTTCTTCGACCACTTCCTCCCCGGGAAACCGTGAGAC 
ValIleArgAlaLysValValGlyLysLysLeuValLysGluGlyProPheGlyThrLeu 
                            50                            60 
 
181                                                      240 
GTCTACACTATTAAGCAGATGAAGATGTACCGAGGCTTCAGTAAGATGCCCCACGTGCAG 
---------|---------|---------|---------|---------|---------| 
CAGATGTGATAATTCGTCTACTTCTACATGGCTCCGAAGTCATTCTACGGGGTGCACGTC 
ValTyrThrIleLysGlnMetLysMetTyrArgGlyPheSerLysMetProHisValGln 
                            70                            80 
 
241                                                      300 
TACATTCACACGGAAGCCTCTGAAAGTCTTTGTGGCCTCAAGCTAGAAGTCAACAAATAC 
---------|---------|---------|---------|---------|---------| 
ATGTAAGTGTGCCTTCGGAGACTTTCAGAAACACCGGAGTTCGATCTTCAGTTGTTTATG 
TyrIleHisThrGluAlaSerGluSerLeuCysGlyLeuLysLeuGluValAsnLysTyr 
                            90                           100 
 
301                                                      360 
CAGTACCTGCTGACAGGGCGCGTGTATGAAGGCAAGATGTACACAGGACTGTGCAACTTT 
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---------|---------|---------|---------|---------|---------| 
GTCATGGACGACTGTCCCGCGCACATACTTCCGTTCTACATGTGTCCTGACACGTTGAAA 
GlnTyrLeuLeuThrGlyArgValTyrGluGlyLysMetTyrThrGlyLeuCysAsnPhe 
                           110                           120 
 
361                                                      420 
GTGGAGAGGTGGGACCACCTCACACTGTCCCAGCGCAAGGGCCTCAATTACCGCTACCAC 
---------|---------|---------|---------|---------|---------| 
CACCTCTCCACCCTGGTGGAGTGTGACAGGGTCGCGTTCCCGGAGTTAATGGCGATGGTG 
                                                    CGATGGTG 
ValGluArgTrpAspHisLeuThrLeuSerGlnArgLysGlyLeuAsnTyrArgTyrHis 
                           130                           140 
 
 
       NdeI 
GCTAGCCATATGTGCAAGATCAAGTCCTGC(Timp3_C_F)                480 
CTGGGTTGCAATTGCAAGATCAAGTCCTGCTACTACTTGCCTTGTTTTGTGACCTCCAAG 
---------|---------|---------|---------|---------|---------| 
GACCCAACGTTAACGTTCTAGTTCAGGACGATGATGAACGGAACAAAACACTGGAGGTTC 
GACCCAACGTTAGAGCTCCGATCG(Timp3_N_R) 
             XhoI 
LeuGlyCysAsnCysLysIleLysSerCysTyrTyrLeuProCysPheValThrSerLys 
                           150                           160 
 
481                                                      540 
AATGAGTGTCTCTGGACCGACATGCTCTCCAATTTTGGGTACCCTGGCTATCAGTCCAAA 
---------|---------|---------|---------|---------|---------| 
TTACTCACAGAGACCTGGCTGTACGAGAGGTTAAAACCCATGGGACCGATAGTCAGGTTT 
AsnGluCysLeuTrpThrAspMetLeuSerAsnPheGlyTyrProGlyTyrGlnSerLys 
                           170                           180 
 
541                                                      600 
CACTACGCCTGCATCCGGCAGAAGGGTGGCTACTGCAGCTGGTACCGAGGATGGGCTCCC 
---------|---------|---------|---------|---------|---------| 
GTGATGCGGACGTAGGCCGTCTTCCCACCGATGACGTCGACCATGGCTCCTACCCGAGGG 
HisTyrAlaCysIleArgGlnLysGlyGlyTyrCysSerTrpTyrArgGlyTrpAlaPro 
                           190                           200 
 
601                              636 
CCAGACAAGAGCATCAGCAACGCCACAGATCCCTGA 
---------|---------|---------|------ 
GGTCTGTTCTCGTAGTCGTTGCGGTGTCTAGGGACT 
              GTCGTTGCGGTGTCTAGGGGAGCTCCGATCG(Timp3_C_R) 
                                  XhoI 
ProAspLysSerIleSerAsnAlaThrAspProEnd 
                              211 
 
 
Figure 3. Primary structure of murine TIMP3. The nucleotide sequence of TIMP3 and the corresponding 
amino acid translation (Apte et al., 1994a and 1994b; Sun et al., 1995). The polypeptide chain is 
composed of 211 amino acids and the quaternary structure contains 188 amino acids. The remaining 23 
residues are the signal sequence (represented in the figure by the underlined amino acid sequence) which 
direct the inhibitor molecule to the extracellular matrix to perform its biological function. For the 
construction of the bacterial expression vector containing TIMP3 (full length TIMP3 and its individual 
domains) primers sequences are given and the restriction sites used in the cloning procedure are in bold. 
The oligonucleotides used for amplification are indicated with their corresponding annealing sites. 
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After transformation of the ligation products into the E coli strain XL1 blue several 
clones were picked from the colonies which had grown. To check for the presence of 
the insert, colony PCR was performed by adding a bacterial colony to a PCR reaction as 
template. In parallel, to further analyse the obtained clones, plasmid DNA was prepared 
and digested with restriction enzymes. Two colonies containing the right insert size 
(based on restriction digestion and the colony PCR) were chosen from each ligation for 
sequencing with the pET_F/pET_R primers. The forward sequencing primer anneals to 
the vector sequence in the region of the T7 promoter, whereas the reverse primer is 
localized to the T7 terminator sequence. 
 
3.1.2 Purification and refolding of recombinant proteins expressed in 
the bacterial system  
The BL21 (DE3) E. coli strain was used for protein expression because this E. coli 
strain has the gene for T7 RNA polymerase inserted in its genome under the control of 
the lac promotor/operator. Protein synthesis is induced by IPTG which binds to the lac 
repressor causing a conformational modification which prevents binding to the lac 
operator. This leads to transcription of T7 RNA polymerase and in turn this polymerase 
recognises the T7 promoter on the vector and transcribes the inserted cDNA, leading to 
recombinant protein synthesis. 
Production of bacterial recombinant TIMP proteins was performed in 1 liter of LB 
medium. Protein synthesis was induced by adding isopropyl-β-D-thiogalactopyranosid 
(IPTG) to a final concentration of 1mM when the OD550 of the bacterial culture reached 
1, and expression of proteins was allowed overnight at 30°C. After centrifugation and 
lysis, inclusion bodies were denatured in 6 M guanidine-hydrochloride and recombinant 
proteins purified by immobilized metal affinity chromatography (IMAC). To obtain 
biologically active protein, the denatured TIMPs were refolded in a buffer with a high 
concentration of arginine and oxido-reducing agents. After the whole procedure was 
completed, bacterial recombinant proteins were analysed by SDS-PAGE for the 
presence of refolded TIMPs and also for purity (Fig. 4). Coomassie stained gels show 
that there are no major non-TIMP3 protein contaminants in the preparation. Refolded 
recombinant WT-TIMP3 and S156C-TIMP3 appear as a doublet, one band at 
approximately 22 kDa and the other at 23 kDa. The slower migrating band might 
correspond to incorrectly folded protein. The N- and the C-terminal domains of TIMP3 
were expressed in bacteria and analysed by SDS-PAGE. These two TIMP3 fragments 
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were homogeneous on the gel and under non-reducing conditions both fragments ran at 
a lower apparent molecular mass, suggesting that the protein has a compact structure 
due to correctly formed disulfide bonds (data not shown). Full length TIMP1, TIMP2 
and TIMP4 were also expressed in E. coli. Refolded forms of these proteins appeared 
on an SDS gel as a major band of the correct molecular weight, but a minor fraction of 
the protein also appeared as a higher molecular weight form with the apparent size of a 
dimer. The yield of refolded protein varies between 1 and 10 % of the initial amount of 
the inclusion bodies.  
 
 
 
 
 
 
 
 
 
 
Figure 4. Characterization of bacterially expressed recombinant proteins by SDS-PAGE. Recombinant 
proteins with a hexahistidine tag fused to the C-terminal were expressed in inclusion bodies, purified via 
IMAC and refolded. Prior to loading to the gel, refolded proteins were incubated with β-mercaptoethanol 
as reducing agent and separated on a 15 % SDS gel, followed by staining with coomassie brilliant blue. 
 
 
The recombinant catalytic domains of TACE and MMP13 were expressed in a similar 
manner to full length TIMP3. After purification, proteins were refolded for 2 days then 
dialysed against PBS. Analysis of these recombinant proteins by SDS-PAGE (Fig. 4) 
revealed that TACE-CD ran as a single band at a molecular weight corresponding to the 
catalytic domain, without major impurities. On a coomassie stained gel MMP13 showed 
two bands (Fig. 4) with equal intensities: one band which corresponds to full length 
MMP13 with a molecular weight of 55 kDa and a smaller fragment at 25 kDa. The 
lower band represents the C-terminal domain of the enzyme (Knäuper et al., 1996) 
which presumably results from autocatalytic cleavage. 
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3.1.3 Construction of a bacterial expression vector for the production 
and purification of antibody epitope peptides fused to GST 
For testing the binding and specificity of commercially purchased antibodies to 
their epitopes, sequences corresponding to the peptide epitopes were amplified and 
cloned into the pGEX-4T3 bacterial expression vector so that the peptide sequence is 
fused to the cDNA of GST. The ADAMTS4 antibody used recognises an epitope in the 
peptide Ala596 to Gln626 and this sequence was amplified using the primer pair 
ADAMTS4_E_F/ADAMTS4_E_R. The epitope recognised by the aggrecan antibody 
was amplified using Agc_E_F/Agc_E_R. The antibody to the Aggrecan neoepitope 
(generated by the cleavage of aggrecan by ADAMTS4/5) is raised against the human 
sequence Gly344 to Glu373. This sequence, and the corresponding sequence from the 
mouse was amplified using the Pept_Gm_F/Pept_Gm_R and Pept_Gh_F/Pept_Gh_R 
primer pairs respectively. The mouse and the human neoepitopes were cloned 
separately because there is one amino acid difference between the mouse and human 
neoepitope sequences: the human sequence is NITEGE while the mouse sequence is 
NVTEGE. This allows the specificity of the neoepitope antibody in recognising both 
neoepitope sequences to be tested. Finally Pept_GA_F/Pept_GA_R were used to 
amplify a peptide containing the ADAMTS4/ADAMTS5 cleavage site which is used as 
a negative control for the neoepitope antibody.  
All epitope fragments were amplified using a mixture of Pfu/Taq polymerase from 
template cDNA isolated from WT chondrocytes. After restriction digest of the PCR 
products with BamHI and NotI they were ligated directly into pGEX-4T3 vector and 
transformed into E.coli. From each transformation 8 colonies were picked and the size 
of the inserts analysed by colony PCR. The identity of the DNA sequences was verified 
by sequencing. The correct constructs were transformed into E. coli strain BL21 and the 
proteins expressed in a 50 ml culture. Production of the peptides fused to GST was 
induced with 0.1 mM IPTG when the optical density of the bacterial culture reached the 
value of 1 at 550 nm. GST fusion proteins are expressed in a soluble form in the cytosol 
of the bacteria, therefore after disruption of the cells the soluble fraction was applied to 
glutathione beads. After several washing steps the GST tagged peptides were eluted 
with reduced glutathione. Recombinant protein analysis by coomassie stained SDS-
PAGE (Fig. 5), revealed that all proteins ran as a single band corresponding to the 
molecular mass of GST fused to the peptides, with the exception of the aggrecan 
epitope which appeared as 4 bands. The largest protein has a molecular mass 
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corresponding to the full length protein so it can be assumed that the lower bands are 
proteolytic degradation products of the full length fusion protein. The yield of the 
proteins was variable, the highest was for ADAMTS4 epitope whereas the lowest was 
for the peptide which contains the cleavage site for ADAMTS4/ADAMTS5 (this 
fragment is designated as uncleaved aggrecan). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. SDS-PAGE analysis of the expressed peptides fused to GST. Peptides corresponding to the 
antibody epitopes were cloned as fusion proteins with GST, expressed in bacterial stain BL21 and 
purified from the soluble fraction of the disrupted bacteria via glutathione beads. Before running the gel, 
the samples were reduced by adding β-mercatoethanol.  
 
 
3.1.4 Generation of a mammalian expression vector for production of 
the extracellular domain of human DDR2 and its expression in 
HEK-293 cells 
DDR2 (Discoidin-domain receptor 2) is a member of a subfamily of receptor 
tyrosine kinases. Binding of fibrilar collagens to DDR2 results in tyrosine kinase 
activation (Vogel W. 1999). The extracellular domain of this receptor was used as a 
positive control in tests of binding of TIMP3 to collagens. DDR2 is an 855 amino acid 
transmembrane protein and in order to express it in a soluble form to perform ELISA 
experiments it was necessary to clone the extracellular domain of this receptor without 
the transmembrane and cytoplasmic regions. The full length construct was cloned into 
the pCEP4 vector with the 1D4 tag attached to its C-terminus. The extracellular domain 
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of DDR2 consists of the first 400 amino acids and for cloning of this region the full 
length construct was digested with BamHI restriction enzyme which cleaves at three 
sites; at the boundary of the extracellular domain and the transmembrane region, 
immediately before the 1D4 tag and in the middle of the cytoplasmic domain. Digestion 
with BamH I leaves sticky ends which were filled by using Klenow polymerase to 
generate blunt ends in the plasmid containing the extracellular domain of DDR2 before 
religation. The recombinant plasmid containing the extracellular domain of DDR2 
(ECD-DDR2) in pCEP4 1D4 vector was verified by restriction digest before 
transfection into HEK-293 cells for overexpression. Protein production was allowed for 
two days in serum free medium to facilitate concentration of the conditioned medium. 
20 ml of the cell culture supernatant was concentrated to 1.5 ml and an aliquot was 
analysed by western blotting for the presence of the overexpressed protein, using an 
anti-1D4 tag antibody (Fig. 6A). To further analyse the recombinant ECD-DDR 
expressed in mammalian cells an ELISA experiment was employed. As Fig. 6B shows 
the extracellular domain of DDR2 was able to bind to collagen type V in a 
concentration dependent manner, whereas it did not interact with BSA (negative 
control).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Western blotting analysis of overexpressed ECD-DDR2 and TTR in HEK-293 cells. (A) 
Subconfluent cells were transfected with 10 µg of plasmid DNA by the calcium phosphate method. The 
transfected cells were grown in serum free medium for two days and the conditioned medium was 
harvested. After concentration of the conditioned medium, the samples were loaded on a gel and then 
blotted onto a hydrophobic membrane. Both proteins were detected with anti 1D4 antibody. (B) ELISA 
for analysis of ECD-DDR2 binding specificity. The wells of a microtiter plate were coated with collagen 
type V (10 µg/ml) or BSA. After blocking, the concentrated conditioned medium from HEK-293 cells 
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transfected either with ECD-DDR2 or TTR were applied in a dilution series. Recombinant protein was 
detected with HRP conjugated anti-1D4 tag antibody and the colourimetric reaction measured at 450 nm. 
The concentration of the recombinant proteins was plotted against the corresponding absorption values. 
The points in the graph are fitted according to equation (8).  
 
 
TTR (transthyretin) was used as a negative control for the collagen binding 
assay. TTR is a serum tetrameric protein of four identical subunits with a molecular 
mass of 14 kDa per monomer and is a carrier of thyroxine and retinol-binding protein 
(Sousa et al., 2001). This protein was cloned also in pCEP4 with the 1D4 tag fused to 
the C-terminal and overexpressed in HEK-293. Western blot analysis (Fig. 6A) shows 
that the TTR is expressed and secreted in the conditioned medium of the transfected 
cells. 1D4 antibody detected two bands, one corresponding to the monomeric form of 
the protein and the other for the dimeric structure. In the collagen binding assay 
recombinant TTR did not bind to collagen type V (Fig. 6B) 
 
 
3.2 Functional analysis of recombinant proteins expressed in E. coli 
 
3.2.1 Bioactivity assessment of recombinant TIMPs by reverse 
zymography 
Recombinant mammalian proteins expressed at high levels in E. coli are most 
often found in inclusion bodies. This has the disadvantage that in this form the proteins 
are not biologically functional as they are deposited as denatured, unfolded polypeptide. 
To achieve bioactivity these proteins must be refolded in vitro and the refolded 
recombinant proteins should be analysed for their functionality before they can be used 
in assays. The most commonly used method for investigating the inhibitory activity of 
TIMPs towards MMPs is reverse zymography. This method is based on electrophoretic 
separation of TIMPs in a SDS-PAGE gel which incorporates MMPs and their substrate 
- gelatin. Where TIMPs are present in the gel MMP activity is inhibited and gelatin is 
not cleaved, whereas in the rest of the gel the gelatin is digested by MMPs activity. 
Therefore, on the gel a dark band (given by the inhibited MMPs-mediated gelatin 
degradation) on a light blue background indicates the presence of active TIMP.  
Reverse zymographic analysis of TIMP1, TIMP2 and TIMP4 showed that these three 
refolded recombinant proteins are able to inhibit the gelatinolytic activity of MMPs 
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(Fig. 7). It is also observed on the gel that the dimeric forms of TIMP2 and TIMP4 are 
also capable of inhibiting MMPs activity. The two individual domains of TIMP3 – the 
N-terminal domain and the C-terminal domain – were also checked for inhibitory action 
against MMPs. As expected, the N-terminal domain of TIMP3 inhibited the 
gelatinolytic activity of MMPs, consistent with the observation that the N-terminal 
region of TIMP3 is responsible for the metalloproteinases inhibition, whereas the C-
terminal domain of TIMP3 was not able to block MMPs activity (Fig. 7). Full length 
WT-TIMP3 and the S156C-TIMP3 mutant could not be analysed by reverse 
zymography because under non-reducing conditions the recombinant protein did not 
enter the gel. TIMP3 also would not run into normal SDS-PAGE under non-reducing 
conditions, probably due to the high concentration of arginine in the refolding buffer. 
 
 
 
 
 
 
 
 
 
Figure 7. Reverse zymogram analysis of TIMP activity. Refolded recombinant TIMPs were separated 
under non-reducing conditions on a 15 % SDS gel containing gelatin and conditioned medium from 
HT1080 fibrosarcoma cell line as a source of MMPs. The gel was incubated in a buffer with Triton X-100 
to replace the SDS from the gel and afterwards incubated overnight at 37°C for the digestion of the 
gelatin by MMPs. Finally, the gel was stained with coomassie blue. 
 
 
3.2.2 Fluorometric titration of MMP13 for the functional assay of 
full-length TIMP3 
Due to the fact that it was not possible to assess the activity of bacterially 
expressed full-length WT-TIMP3 and S156C-TIMP3 by reverse zymography, these 
recombinant proteins were assayed for bioactivity by fluorescence titration against 
MMP13 (Collagenase 3). MMP13 is a 55 kDa secreted matrix metalloenzyme which 
preferentially hydrolyzes collagen type II with high efficiency, and has lower cleavage 
activity against collagen type I and III (Knäuper et al., 1996). 
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Prior to performing the inhibitory assay, MMP13 was activated by incubation with 1 
mM APMA (4-Aminophenylmercuric acetate) at 37°C for 2 h. To test TIMP3 inhibitory 
activity, a concentration dependence curve was made by incubating a constant amount 
of activated enzyme with increasing concentrations of WT-TIMP3 and S156C-TIMP3 
in an assay using a quenched MMP13 fluorogenic substrate specific for collagenase 3. 
Fluorescence was plotted against the concentration of TIMP3 used for the inhibitory 
assay, with a decrease in fluorescence showing inhibition of MMP13 activity. The 
results show that both WT-TIMP3 and mutant TIMP3 are able to reduce the cleavage 
activity of MMP13 in a concentration dependant manner (Fig. 8). These data indicate 
that bacterially expressed full-length WT-TIMP3 and S156C-TIMP3 are able to inhibit 
the catalytic activity of MMP13 after in vitro refolding, and shows that these two 
recombinant proteins are active and mainly correctly folded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Fluorometric titration of MMP13. Mouse recombinant collagenase 3 was expressed in bacteria 
in inclusion bodies, purified and refolded. The enzyme was activated by incubation in 1 mM APMA for 2 
h at 37°C. A constant amount of activated MMP13 was incubated with recombinant TIMP3 for 2 h at 
room temperature. 2 hours after adding the fluorogenic quenched substrate to the reaction mixture, 
fluorescence was measured at 330 nm excitation and 390 nm emission. The fluorescence given by the 
uncomplexed MMP13 was plotted against the concentration of TIMP3. The error bars represent ±SD of 
three independent experiments. 
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3.2.3 Analysis of antibody binding to epitopes and their specific 
recognition 
Commercial antibodies were tested by ELISA for binding to recombinant 
expressed epitopes fused to GST and specific recognition of their corresponding 
epitopes. An ELISA was used because all experiments involving these antibodies were 
done using this assay. ADAMTS neoepitope antibody bound specifically to the 
recombinant fused protein. Both the human and the mouse epitope were recognised, but 
not the uncleaved peptide containing the recognition site (Fig. 9A). The specificity of 
the antibody was further tested in an ELISA using different cell lines. For this propose, 
three cell lines were chosen as positive and negative controls. Isolated primary 
chondrocytes which express aggrecan and ADAMTS4/5 are positive controls for the 
antibody specificity. Fibroblasts and RAW 264.7 are the negative controls as they do 
not express the condrocyte markers (see fig. 16 and Thomas Langmann, personal 
communication). These cell lines were grown in ELISA plate wells and probed with 
antibodies which bind to aggrecan, ADAMTS4, ADAMTS neo and MMP neo epitopes. 
As Fig. 9B shows the antibodies specifically recognise their protein-antigens in the 
ELISA. Therefore, this ELISA experiment shows that the antibody interacts specifically 
with its neoepitope and can be used as a positive control in the ADAMTS4/ADAMTS5 
mediated cleavage of aggrecan. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Analysis of antibody specificity and selectivity in ELISA. (A) ELISA determination of binding 
between the neoepitope antibody and its epitopes. An ELISA plate was coated with purified peptides 
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fused to GST, blocked and serial dilutions of the anti-ADAMTS neo antibody was applied. Antibody 
bound to the peptide was detected with anti rabbit antibody conjugated to horse radish peroxidase and the 
absorbance values at 450 nm were plotted against the antibody concentration. A curve was fitted to the 
points using the equation (8). (B) 1.5x104 cells were plated on a microtiter plate and grown for 5 days. 
The primary antibodies were applied to the different cell lines followed by the secondary antibody. After 
adding the enzyme’s substrate, the absorbance of the chromogenic reaction was measured at 450 nm. The 
plots represent three point readings with ±SD as error bars. 
 
 
3.3 Functional implications of TIMP3 on TACE catalytic activity 
TIMP3 is unique among the TIMPs in that it is able to inhibit TACE (TNF-alpha 
converting enzyme) mediated shedding of membrane bound TNF-α. To determine 
whether inhibition of TACE activity is influenced by the S156C-TIMP3 point mutation, 
total protein from liver extracts was isolated by homogenation of whole liver of mice 
heterozygous  (KI het) or homozygous (KI hom) for the S156C-TIMP3 knock-in as well 
as from wild type (WT) and TIMP3 knock out (KO) mice. Liver was chosen because it 
has been reported that TACE activity in the TIMP3 knock-out mouse is upregulated in 
this organ (Mohammed et al., 2004). If the S156C mutation in TIMP3 molecule has an 
effect on TACE inhibition then it should be measurable in liver. TACE activity was 
assessed using a fluorogenic substrate (TACE substrate II) specific for this enzyme, in 
which the cleavage activity of TACE is measured by increased fluorescence of the 
cleaved peptide. This fluorogenic substrate consists of a short peptide containing a 
TACE-specific cleavage sequence separating the fluorescent group from dinitrophenyl 
group that acts as an internal quencher. 
As shown in the Fig. 10 both native TACE from the liver extracts and recombinant 
TACE catalytic domain cleaved the fluorogenic substrate and displayed saturation 
kinetics for hydrolysis of the fluorogenic peptide. 
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Figure 10. Substrate hydrolysis by native TACE from liver extracts and recombinant TACE catalytic 
domain. (A) 200 µg of liver extract from animals of different genotypes were mixed with increasing 
concentration of fluorogenic TACE substrate II (100 nM to 5000 nM) and incubated for 1 hour at 27°C 
before measurement of fluorescence at 330 nm excitation and 390 nm emission. (B) 100 nM of rTACE 
catalytic domain was incubated with fluorogenic substrate (100 nM to 3200 nM) for 1 hour at 27°C and 
the fluorescence was measured as above. The fluorescence values obtained were plotted against the 
corresponding concentrations of the substrate. A curve was fitted to the points using the equation (8). 
 
 
The activity of the enzyme in the liver extract of mice heterozygous  (KI het) or 
homozygous (KI hom) for the S156C-TIMP3 knock-in shows that there is no change in 
the rate of fluorogenic substrate hydrolysis compared to their WT counterparts (Fig. 
11). As expected, the loss of TIMP3 protein (KO hom) leads to the upregulation of 
TACE activity and it is in good agreement with other published data (Mohammed et al., 
2004).  
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Figure 11. Analysis of TACE activity in liver extracts. 200 µg of total liver protein extract was incubated 
with 1 µM of TACE fluorogenic substrate for 1 hour at room temperature before the fluorescence was 
measured at 27°C using 330 nm excitation and 390 nm emission. The plots represent the means of three 
independent measurements. The error bars represent ±SD. 
 
 
In order to assess the specificity of the measurements and to attribute the inhibition of 
TACE to TIMP3, we incubated the liver extract with recombinant WT-TIMP3, S156C-
TIMP3, TIMP1, TIMP2 and TIMP4 in a concentration dependent manner. Cleavage of 
the fluorogenic substrate was inhibited by WT-TIMP3 and S156C-TIMP3, whereas 
TIMP1, TIMP2 and TIMP4 had no effect on cleavage of the substrate in the range of 
concentrations used (Fig. 12). 
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Figure 12. Inhibition of native TACE from WT liver extract by rTIMPs. Recombinant TIMPs were 
added to 50µg of total protein extract from WT mouse liver in a concentration dependent manner (25 nM 
to 1000 nM). The TIMPs and TACE were incubated at room temperature for 4 h before 1µM substrate 
was added to the reaction. After a further 3 hours incubation the fluorescence was measured. The graph 
shows the mean of three independent measurements with ±SD as error bar. 
 
 
In order to further prove the specificity of inhibition of TACE by TIMP3, which was 
observed in the whole liver protein extract, inhibition of recombinant TACE catalytic 
domain (rTACE-CD) was examined. In a concentration dependent inhibition assay the 
cleavage activity of rTACE-CD was blocked by both WT-TIMP3 and S156C-TIMP3 to 
the same extent (Fig. 13), as native TACE from liver extracts of WT, KI het and KI 
hom animals. As a negative control, rTACE-CD was incubated with increasing amounts 
of: TIMP1, TIMP2 and TIMP4. As expected, hydrolysis of the fluorogenic substrate 
was not significantly inhibited by these TIMPs. 
 
 
 
 
Figure 13. Assessment of rTACE-CD inhibition by rTIMPs. Recombinant TACE catalytic domain (100 
nM) was incubated with increasing concentrations of TIMPs (6 nM to 220 nM) for 3 h at RT. 1µM of 
0
2500
5000
7500
10000
12500
15000
17500
0 25 50 75 100 125 150 175 200 225 250
[Timps] nM
Fl
ou
re
sc
en
ce
 (a
rb
itr
ar
y 
un
its
)
WT-Timp3
S156C-Timp3
Timp1
Timp2
Timp4
Results 
 59
TACE  fluorogenic substrate was added to the reaction and the fluorescence was measured after a further 
2 h incubation at 27°C. Graph represents the mean value of 3 independent experiments. 
 
 
As TIMP3 is capable of inhibiting the cleavage activity of TACE, binding of TIMP3 to 
rTACE-CD was analysed by ELISA. The experimental data demonstrates that TIMP3 
can bind to the TACE catalytic domain in a concentration dependent manner and that 
the S156C-TIMP3 mutant binds with similar affinity to WT-TIMP3 (Fig. 14) 
suggesting again that the SFD related mutation does not affect TACE activity both in 
vivo and in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 Analysis of TIMP3 binding to TACE catalytic domain. Wells of a microtiter plate were coated 
with purified and refolded TACE catalytic domain overnight at 4°C. After blocking with BSA, serial 
dilutions of TIMP3 were applied and incubated for 1 hour at room temperature. The TIMP3 bound to 
TACE was detected with an anti-TIMP3 polyclonal antibody followed by incubation with a peroxidise 
conjugated rabbit secondary antibody. The intensity of the chromogenic reaction generated in the 
presence of TMB was plotted against the corresponding TIMP3 concentration and the curves were fitted 
according to equation (8). 
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3.4 Cleavage activity of ADAMTS4/ADAMTS5 and MMPs inhibition 
by TIMP3 
ADAMTS4 (aggrecanase-1) and ADAMTS5 (Aggracanase-2) are two 
metalloenzymes which are secreted and bound to the ECM and whose best 
characterised activity is for cleavage of aggrecan. The proteoglycan aggrecan is the 
major component of cartilage ECM that gives it the strength to resist to high loads. 
TIMP3 is able to inhibit the cleavage activity of these two matrix metalloenzymes 
(Kashiwagi et al., 2001), although they can also be inhibited by other members of the 
TIMP family, although with lower efficiency (Hashimoto et al., 2001). The aggrecan 
molecule can also be cleaved by MMPs but the cleavage site is different to that of the 
ADAMTSs (Fig. 15). The specific cleavage activity of these two types of enzymes can 
be monitored by so-called neoepitope antibodies which recognise the amino acid 
sequence exposed after proteolysis of aggrecan. Neoepitope antibodies can react with 
either the C-terminal or the N-terminal sequence of the epitope generated by the action 
of a specific matrix metalloenzyme. 
 
Figure 15. Schematic representation of MMPs and ADAMTS cleavage sites in the core Aggrecan 
molecule. The proteoglycan consists of several regions with high glucosaminoglycan content. G1- first 
globular domain; IGD-intraglobular domain; G2- second globular domain; KS- aggrecan region rich in 
keratin sulfate; CS-1 and CS2- regions one and two highly glycosylated with chondroitin sulfate. CS-2 
contains gaps in glycosylation where the cleavage site for aggrecanases is located. G3- third globular 
region, representing the most C-terminal domain of the core proteoglycan. The arrows indicate the 
cleavage sites for aggrecanases and MMPs. The neoepitope sequences used in the present study and 
generated by MMPs and ADAMTS4/ADAMTS5 are highlighted in the figure. 
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In order to investigate TIMP3 function in the context of ADAMTS4/ADAMTS5 
mediated aggrecan cleavage, chondrocytes were isolated from the ribs of mice deficient 
in TIMP3 and with the knock-in mutation (S156C-TIMP3) by treating them with 
collagenase. To test the identity of the isolated cells, immunocytochemistry was 
performed for the chondrocyte marker collagen type II. The cells were stained with 
antibody 5109 (Downs et al., 2001), which recognises collagen type II. The cells 
showed an intense fluorescence demonstrating that the isolated cells are chondrocytes 
(Fig. 16A). The cells were further tested for another chondrocyte marker, aggrecan. In 
immunocytochemistry the anti-aggrecan antibody detected aggrecan localized in the 
ECM surrounding the cells. In addition the cells were immunostained with antibodies 
recognising the aggrecan neoepitopes generated by the action of MMP and 
ADAMTS4/ADAMTS5 (data not shown). 
For further characterization of the cells, RT-PCR was performed on RNA isolated from 
chondrocytes and fibroblasts (Fig. 16B). The primer pairs were chosen in such a way 
that they anneal to two different exons, to eliminate the possibility of contamination of 
the RNA preparation with genomic DNA. Another parameter taken into consideration 
when designing the primers was that they are localized close to the 3’ end of the 
transcripts. The cDNA was synthesized using oligo dT primer which anneals at the 
polyA signal at the 3’ end, using primers designed to bind to the 3’ end increases the 
probability that transcripts with lower expression level are amplified. In the case of very 
long mRNAs the ability of reverse transcriptase to synthesise the full length cDNA 
decreases along with the yield of the full length product. 
In RT-PCR experiments the GUS (β-glucuronidase) house keeping gene was used as a 
control for RNA integrity. Experimental data revealed that only the chondrocytes 
express aggrecan - the substrate of ADAMTS4/ADAMTS5 – whereas fibroblasts do not 
(Fig. 16B). The other two transcripts analysed by RT-PCR were 
ADAMTS4/ADAMTS5 and it can be observed that both cell lines express the two 
matrix metalloenzymes. Supplementary information which can be extracted from the 
semiquantitative RT-PCR data suggests that at the RNA level the expression profile of 
the transcripts are not affected by the absence of TIMP3 or by the presence of the 
TIMP3 mutation in the mutant mice. The data obtained from RT-PCR and 
immunocytochemistry suggest that the isolated cells are chondrocytes, express the 
Results 
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enzymes and substrate (unlike the fibroblasts) and so provide a suitable system for 
analysis of the influence of TIMP3 on these proteinases. 
 
 
 
 
Figure 16. Characterization of isolated primary chondrocytes. (A) Representative staining of collagen 
type II in cultivated chondrocytes by immunocytochemistry. WT chondrocyte cells were grown on cover 
slips and fixed with 4% paraformaldehyde. After blocking the cells, an antibody specific for collagen type 
II was added, followed by incubation with an anti-mouse IgG antibody conjugated to Alexa Fluor 594. 
Collagen type II staining appears in red and the nuclei are stained with DAPI (4’,6-Diamidin-2’-
phenylindol-dihydrochlorid) in blue. The image was taken with Carl Zeiss Axioscop 2 fluorescence 
microscope with a magnification of 40x. (B) RT-PCR expression analysis of aggrecan and 
ADAMTS4/ADAMTS5 in chondrocytes. RNA was isolated from chondrocytes and fibroblasts and first 
strand cDNA was prepared using 1 µg of RNA. The genes were amplified using a touch down PCR 
program with the primer pairs annealing to two different exons. The fragments amplified have the 
following sizes; Aggrecan - 250 bp; ADAMTS4 – 306 bp; ADAMTS5 – 302 bp and Gusb - 198 bp. Gus 
house-keeping gene was used as a control to check for the cDNA quality. 
 
 
Two neoepitope antibodies were used to analyze the cleavage rate of aggrecan, namely 
ADAMTS neo (this antibody recognizes the C-terminal amino acid sequence - TEGE373 
- formed after cleavage by ADAMTS4 or ADAMTS5) and MMP neo (the C-terminal of 
MMP cleaved Aggrecan - DIPEN341 - is recognized by this antibody). These two 
aggrecan neoepitope fragments are retained in the ECM bound to hyaluronan (Fosang et 
al., 2003), making it possible to detect them by immunohistochemistry.  
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To investigate the cleavage rate of aggrecan due to the matrix metalloenzymes a 
modified ELISA was employed. In principle, this assay is based on chondrocytes grown 
in a monolayer in the wells of ELISA plate. The cells were cultured for 7 days, followed 
by a further 2 days in serum free medium, then fixed with paraformaldehyde and 
blocked with 3% BSA. The primary antibody was added to the wells and incubated 
overnight at 4°C followed by incubation with the secondary antibody conjugated with 
horse radish peroxidise. The end point value was measured after the chromogenic 
reaction was stopped with 1 N HCl at 450 nm. The native cleavage of aggrecan can be 
quantified using this assay which provides an approximation of the in vivo situation. 
Using the neoepitope antibody which recognises the C-terminal sequence generated by 
ADAMTS4/ADAMTS5 cleavage, ELISA experiments show that there are equal levels 
of cleavage (neoepitope) in TIMP3 knock-out and S156C-TIMP3 knock-in 
chondrocytes when they are compared with the WT counterpart (Fig. 17A). 
Quantification for total aggrecan content by using an antibody which reacts with the 
uncleaved part of the Aggrecan shows that the levels of Aggrecan amount in the wild-
type and mutant chondrocytes are similar (Fig. 17B). The level of the two enzymes 
responsible for the Aggrecan cleavage –ADAMTS4 and ADAMTS5- are also 
unchanged in all cell lines analyzed (Fig. 17C and D).  
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Figure 17. Measurement of ADAMTS4/ADAMTS5 generated Aggrecan fragments in chondrocyte-
ELISA assay. Detection of the neoepitope generated by ADAMTS4/ADAMTS5 (A), total Aggrecan 
levels (B), ADAMTS4 levels (C) ADAMTS5 levels (D). Freshly isolated chondrocytes from animals 
with different genotypes were seeded on an ELISA plate and grown for 7 day and further 2 days in serum 
free medium. The cells were incubated with the primary antibody and the bound antibody was detected 
with the secondary antibody conjugated with HRP. After addition of substrate the end point absorbance 
was measured at 450 nm. The plots represent the mean value of 3 independent experiments with ±SD as 
error bar. 
 
 
The second group of metalloenzymes which are involved in the catabolism of aggrecan 
are the MMPs and they cleave aggrecan molecules at a distinct site from that of 
ADAMTS4/ADAMTS5 (Westling et al., 2002). Using an antibody which detects the 
neoepitope revealed by MMP cleavage of Aggrecan, the level of Aggrecan proteolysis 
is unaltered in the mutant cell lines compared to WT (Fig. 18A). MMP activity in 
conditioned medium from the TIMP3 mutant cell lines was also checked by gelatin 
zymography. As reported earlier for fibroblasts (Soboleva et al., 2003), MMP2 activity 
secreted by chondrocytes was unchanged in the cell lines tested (Fig. 18B). 
 
 
 
 
 
 
 
 
 
Figure 18 Detection of MMPs mediated aggrecan cleavage (A) and zymography analysis of MMPs 
activity (B). Isolated chondrocytes from each genotypes were plated in the wells of an ELISA plate, 
grown for 7 days followed by two more days in serum free medium. The MMPs cleavage activity was 
detected in an ELISA using the neoepitope antibody specific for the C-terminal of MMP cleaved 
aggrecan. The absorbance represents the mean values of 3 independent measurements and ±SD as error 
bar. (B) Serum free conditioned medium from cultured chondrocytes were applied to zymography and 
analysed for cleavage of the gelatin from the gel.  
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To analyse if the MMPs mediated cleavage of aggrecan can be blocked in vitro by 
recombinant TIMPs, chondrocytes of all four genotypes were treated with 100 ng/ml 
inhibitors for two days in medium with serum and two additional days in serum free 
medium, changing the medium every day. All TIMPs were able to inhibit MMPs 
mediated cleavage of Aggrecan by decreasing the amount of detected neoepitope (Fig. 
19). 
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Figure 19. In vivo inhibition of the MMPs mediated aggrecan cleavage by recombinant TIMPs in cell-
based ELISA. Chondrocytes from WT (A), S156C KI het (B), S156C KI hom (C) and TIMP3 KO (D) 
were grown on ELISA plates for 9 days and treated with 100 ng/ml inhibitors for the last 4 days. After 
fixing the cells, MMP neoepitope antibody was applied overnight and the bound primary antibody was 
detected with peroxidase conjugated goat anti-mouse IgG antibody. The end point absorbance was 
measured at 450 nm and the plots represent the mean value of three point measurements with ± SD as 
error bar. 
 
 
Collagen type II is the second major cartilage protein and it is catabolised by several 
known MMPs such as MMP-1, MMP-8, MMP13 and MT1-MMP (Harris and Krane, 
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1974a, 1974b, 1974c; Hasty et al., 1990, Mitchell et al., 1996; Wernicke et al., 1996; 
Ohuchi et al., 1997). Catabolism of collagen type II by MMPs can be assessed by using 
the 9A4 neoepitope antibody that is able to recognize the C-terminal amino acid 
(GPX771GPQG where X is proline or hydroxyproline) of the 3/4 fragment after 
collagenase cleavage (Otterness et. al. 1999). In experiments performed on the isolated 
chondrocytes the levels of collagen type II neopeitope antibody bound suggest that 
MMP activity is not modified in mice carrying either the TIMP3 deletion or the 
mutation (Fig. 20A). Quantification of uncleaved collagen type II using the 5109 
antibody (Downs et al., 2001), which will measure the total amount of this collagen, in 
ELISA experiments based on cultivated chondrocytes showed that the amount of this 
protein is unchanged in any of the cell lines investigated (Fig. 20B). 
 
 
 
 
 
 
 
 
 
Figure 20. Measurement of collagen type II cleavage by MMPs (A) and the total amount of collagen type 
II (B) in chondrocytes. Chondrocytes isolated from animals with different genotypes were grown in a 96 
well microtiter plate for 9 days. 9A4 antibody was used to detect the cleavage activity of MMPs and 5109 
(Downs et al., 2001) for the detection of uncleaved collagen type II. Bound primary antibody was 
detected with HRP conjugated goat anti mouse IgG and the intensity of the chromogenic reaction in the 
presence of TMB was measured at 450 nm. The plots represent the mean value of three independent 
measurements with ±SD as error bar. 
 
 
3.5 Competitive inhibition of VEGF binding to VEGFR2 by TIMP3 
It has been demonstrated that TIMP3 is able to block angiogenesis by competing 
with VEGF for binding to VEGFR2 (Qi et al., 2003). To investigate the ability of WT-
TIMP3 and the S156C-TIMP3 mutant to compete with VEGF for binding to VEGFR2 a 
competitive ELISA was employed. Incubation of VEGFR2 with increasing 
concentrations of either recombinant wild-type or S156C-TIMP3 proteins diminished 
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the binding of VEGFR2 to VEGF immobilized on ELISA plates (Fig. 21). In contrast, 
TIMP2 was not able to compete with VEGF for its receptor binding and serves as a 
negative control for the binding test (Fig. 21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Competitive inhibition of VEGF binding to VEGFR2 by WT-TIMP3, S156C-TIMP3. 
Increasing concentrations of WT-TIMP3 (diamonds), S156C-TIMP3 (squares), TIMP2 (triangles) were 
added to a constant concentration of VEGFR2 (20 nM) and the complex was incubated overnight at room 
temperature before being added to wells coated with VEGF. VEGFR2 bound to VEGF was detected with 
an antibody directed against VEGFR2. After applying the secondary antibody conjugated with HRP the 
intensity of the chromogenic reaction, was measured at 450 nm. Absorbance values were plotted against 
the corresponding TIMP concentrations. The data plotted is the mean of 3 independent experiments with 
±SD as error bar. 
 
3.6 Analysis of TIMP3 binding to collagens 
In an effort to find new interacting partners of TIMP3 which might help in 
clarifying the SFD pathomechanism several collagens were analysed for their binding to 
TIMP3 in an ELISA. Five types of collagen were used to testing for binding of refolded 
recombinant WT-TIMP3 and the S156C-TIMP3 mutant: collagen type I from rat tail; 
collagen type II from chicken; collagen type III from calf; collagen type IV from human 
placenta and collagen type V from human placenta. The ELISA demonstrated that WT-
TIMP3 (Fig. 22A) and S156C-TIMP3 (Fig. 22B) bound all collagens tested at 
approximately similar levels to wells only coated with BSA. 
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Figure 22. TIMP3 binding to various types of collagens in ELISA. The wells of an ELISA plate were 
coated with 10 µg/ ml solutions of the collagens indicated together with BSA overnight at 4°C followed 
by blocking with BSA. 1µM of recombinant WT-TIMP3 (A) or S156C-TIMP3 (B) was added to the 
collagen coated wells and incubated 1 hour at room temperature. TIMP3 bound to the collagens was 
detected using a polyclonal anti TIMP3 antibody directed against C-terminal of TIMP3 which was 
prepared in house. After incubation with the secondary antibody the intensity of the chromogenic reaction 
was measured at 450 nm. (C) ECD-DDR2 (positive control) and TTR (negative control) binding to 
collagens was performed exactly as for TIMP3 binding to collagens. The plots represent three point 
measurements with ±SD as error bar. 
 
 
To test for the specificity of the entire collagen binding experiment, ECD-DDR2 (Fig. 
6A) was used as a positive control for the collagen binding and TTR (Fig. 6A) was used 
as a negative control. As can be seen from the experimental data TTR does not interact 
with any of the collagens while ECD-DDR2 binds to collagen types II, III and V (Fig. 
22C), as expected, showing that the assay is specific. 
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In order to further analyze the ability of TIMP3 to bind to collagens and apparently non-
specifically to BSA, a concentration dependent ELISA of TIMP3 binding to collagen 
type V was performed. The results of the assay show that full length WT-TIMP3 binds 
to collagen type V in a concentration dependent manner (Fig. 23A). Using the 
individual TIMP3 domains in this ELISA shows that there is no binding of the refolded 
N-terminal domain of TIMP3 to collagen type V while the C-terminal domain binds 
collagen type V with similar affinity to full length WT-TIMP3 (Fig. 23A). The same 
experimental set up was used to test TIMP3 binding to BSA. Application of TIMP3 in a 
serial dilution gives a similar binding pattern as for binding to collagens: the N-terminal 
does not bind to BSA while full length TIMP3 and its C-terminal bind unspecifically to 
the BSA (Fig. 23B). In parallel, the other TIMP family members were analysed for 
binding to collagens and as can be seen in Fig. 23C TIMP1, TIMP2 and TIMP4 do not 
interact with collagen type V, this experiment represents a further control for the 
ELISA. 
In an ELISA the antigen is immobilized by adsorption to the surface of the well. This 
process might cause conformational changes in the immobilized ligand potentially 
leading to unspecific interactions, therefore the interaction of TIMP3 with a molecule in 
solution was investigated.  A pull down assay of TTR by TIMP3 was performed using 
Ni-NTA beads which bind to the His tag fused to the C-terminal of TIMP3. Western 
blot analysis revealed that WT-TIMP3 was able again to bind to an unrelated molecule 
(TTR) in solution (Fig. 23D). 
Taken together, these results suggest that the apparently unspecific interaction of full 
length WT-TIMP3 and S156C-TIMP3 with the collagens is mediated through the C-
terminal domain of TIMP3.  
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Figure 23.  ELISA experiments for analysing the binding activity of TIMP3 to collagen type V. 10 µg/ml 
of human collagen type V (A and C) and BSA (B) was applied to the wells of an ELISA plate and 
incubated overnight at 4°C. The wells were blocked by adding 3% BSA for 1 hour at room temperature. 
Purified and refolded TIMP3 and the TIMP3 N-terminal and C-terminal domains (A and B) and TIMP1, 
TIMP2, TIMP4 (C) were applied in a dilution series and bound TIMP was detected using an anti His tag 
antibody. The intensity of the chromogenic reaction was measured at 450 nm as end point and plotted 
against the corresponding TIMP3 concentration. The data were fitted by non-linear least-squares 
regression according to equation (8). (D) Pull down of TTR by TIMP3. Bacterially expressed TIMP3 was 
mixed with TTR and incubated overnight at 4°C with gentle rotation. Next day washed Ni-NTA beads 
were added to the solution and incubated for a further 2 hours. The beads were washed several times with 
50 mM NaH2PO4, 300 mM NaCl pH 8.0 before the complex was eluted with the above buffer containing 
250 mM imidazole. TTR on the blot was detected with anti 1D4 tag antibody and TIMP3 was detected 
with anti-TIMP3 antibody. 
 
 
3.7 Structural implications of S156C mutation on TIMP3 molecule 
The most common mutation in the TIMP3 gene associated with SFD is the 
introduction of a new free cys residue. Potentially this can mediate the formation of 
intermolecular disulfide bonds leading to oligomerisation of the mutant TIMP3. To test 
this possibility, western blotting was employed for the detection of higher molecular 
weight complexes. For this purpose immortalized fibroblasts cell lines with S156C 
knock-in mutation were used. ECM proteins secreted by fibroblasts were prepared by 
C 
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scraping the surface of cell culture dishes with SDS loading buffer and the samples 
were loaded onto SDS-PAGE in both reducing and oxidizing conditions. Detection of 
TIMP3 under non-reducing conditions in western blots shows that in samples 
containing the mutant TIMP3, both from the KI het and the KI hom fibroblasts, a band 
of approximately 43 kDa (Fig. 24) appears, which could correspond to a dimeric form 
of the S156C-TIMP3 mutant built up due to intermolecular disulfide bonds. This 
assumption is supported experimentally by running the same samples under reducing 
conditions which leads to the dissociation of the 43 kDa complex to the monomeric 
form (Fig. 24). In addition, the mutant S156C-TIMP3 seems to form even higher 
molecular weight complexes localized at the top of the gel which might be explained by 
the formation of aggregates. In contrast, when analysing TIMP3 from the WT 
fibroblasts, no oligomeric or aggregated forms of the protein are seen. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Western blot analysis of S156C mutant TIMP3 versus WT-TIMP3. WT fibroblasts and S156C 
KI fibroblasts were cultured for two days. After removing the cells by trypsinazition, ECM bound 
proteins were solubilised in SDS loading buffer without reducing agent (ß-mercaptoethanol). An aliquot 
from each sample was loaded on a 15% SDS-PAGE under reducing conditions and also under non-
reducing conditions. TIMP3 protein on the blot was detected with a polyclonal antibody directed against 
the C-terminal of TIMP3. 
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3.8 Quantification of the S156C-TIMP3 mutant protein in knock-in 
fibroblasts 
One of the major features found in the eyes of the patients with SFD is the 
formation of drusens containing, among many other proteins, TIMP3. Therefore, as 
S156C KI fibroblasts are available, it was decided to measure the amount of mutant 
TIMP3 protein in these cell lines. The quantity of the TIMP3 was measured in an 
ELISA using fibroblasts grown in the wells of a microtiter plate. We took advantage of 
the fact that in the cell culture system TIMP3 is localized bound to the ECM and after 
cell detachment can be directly detected without further manipulation. This avoids 
errors occurring during protein handling and in the end gives relatively accurate results. 
Moreover, the ELISA is also a quantitative assay compared, for example, with western 
blotting which is more a qualitative method. 
Using the method mentioned above, the amount of TIMP3 was measured in different 
compartments. First an ELISA was performed for TIMP3 bound to ECM. The results 
show that in fibroblasts carrying the S156C mutant TIMP3, both in homozygotes and 
heterozygotes, the amount of extracellular TIMP3 is elevated compared to WT 
counterparts (Fig. 25A). However comparison of KI heterozygous and KI homozygous 
cell lines showed no significant differences in the levels of mutant protein. Next the 
TIMP3 cell content was analysed. Equal numbers of cells were allowed to attach for 2 
hours in the wells of a microtiter plate and their protein content was quantified as 
described for the cell based ELISA. The data obtained demonstrates that the amount of 
TIMP3 is also elevated in fibroblasts cell lines carrying the TIMP3 mutation (Fig. 25B) 
following the same pattern as for the ECM. The total amount of TIMP3, made up of the 
cellular protein together with the ECM bound material was also analysed. Again, the 
amounts of TIMP3 in KI fibroblasts are higher than in wild type cells (Fig. 25C).  
A significant parameter which might influence experimental data when comparing 
different cell lines would be the number of cells (if it is assumed that the cell division 
rate is higher in one cell line compared to the other and the higher cell number would 
produce more protein). Therefore, β-actin was used as a normalization factor for the 
number of the cells. Measurement of the level of this protein suggests that the number 
of the cells are approximately equal (Fig. 25D), so that the increased TIMP3 
concentration in the KI fibroblasts determined by ELISA is due to the mutation in the 
inhibitor molecule and not of the experimental conditions. 
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Figure 25. Measurement of TIMP3 amount in different compartments in fibroblasts. (A) 1.5x104 
fibroblasts were seeded on an ELISA plate and grown for 2 days. The cells were detached non-
enzymatically (cell dissociation buffer enzyme free PBS-based, Gibco) and the ECM bound TIMP3 was 
detected by ELISA. For cellular TIMP3 (B) and β-actin (D), 1.5x104 cells were plated and allowed to 
attach for 2 hours and the amount of TIMP3 and β-actin was measured based on cell ELISA. (C) The 
same number of fibroblasts were grown for 2 days before being fixed with PFA and TIMP3 was detected 
as described for cell based ELISA. The plots represent the mean value of three point measurements with 
±SD as error bar and the data were normalized against β-actin. 
 
 
3.9 TIMP3 turnover in the ECM 
Elevated amounts of mutant TIMP3 in the fibroblasts suggests that either the 
protein is not degraded with the same efficiency as the WT or the mutant transcript is 
upregulated. Reports in the literature show that the mutant mRNA level is not affected 
by the mutation (Chong et al., 2003). To analyse the possibility that the mutant TIMP3 
is degraded more slowly than the WT and therefore leads to the protein accumulation, 
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TIMP3 turnover in the ECM was measured. In principle, the method used is based on 
the following experimental set-up: the KI fibroblasts are grown in the wells of a 
microtiter plate for a certain time before they are removed and replaced by knock-out 
fibroblasts. After different time points the knock-out cells are removed and the 
remaining ECM bound TIMP3 is quantified by ELISA. As the experimental data shows 
(Fig. 26), the rate of S156C-TIMP3 turnover, both in the knock-in heterozygous and 
knock-in homozygous cell lines, is significantly lower in the first two days compared to 
the WT-TIMP3, confirming the hypothesis that the mutant TIMP3 is more resistant to 
degradation and hence that the protein will accumulate in the ECM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Rate of the TIMP3 degradation in the ECM. 1.5x104 KI heterozygous, KI homozygous or WT 
fibroblasts were plated and grown for two days on an ELISA plate before the cells were detached non-
enzymatically and replaced by 6x103 TIMP3 knock-out fibroblasts to measure TIMP3 turnover. After the 
time points indicated in the graph the KO fibroblasts were removed and the remained TIMP3 protein was 
detected with a polyclonal antibody against TIMP3 based on the principle of a regular ELISA. The error 
bars ±SD represents three point readings. 
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4. Discussion 
 
Although SFD is a rare disorder, a number of phenotypical similarities to age 
related macular degeneration (AMD) make it an important disease to be elucidated. At 
present, it is unknown how mutations in TIMP3 initiate the molecular events that lead to 
disease development and progression and finally to the full known picture of SFD 
pathology. 
TIMP3 is a multifunctional protein involved in many biological processes. Of these, the 
best characterised activity is the inhibition of metalloenzymes mainly attributed to the 
N-terminal domain (Lee et al., 2001, Langton et. al., 1998, Wei et al., 2005). It plays 
also a role independent of the enzymatic inhibitory function for which the C-terminus of 
TIMP3 is responsible, namely binding to VEGFR2, EFEMP1 (Klenotic et al., 2004) 
and to the ECM (Langton et al., 1998; Yu et al., 2000) although recent evidence 
suggests that both domains, the N- and the C-terminus, contribute to ECM binding (Lee 
et al., 2007). 
To dissect the pathomechanism of SFD, the present study aimed at deciphering the 
effects of the pathological mutations on functional aspects of TIMP3 biology both in 
vivo and in vitro. We also wanted to investigate whether the known TIMP3 missense 
mutations result in a dominant negative effect or lead to haploinsufficiency. In order to 
obtain insight into the pathological characteristics of SFD, two mouse models of TIMP3 
mutations were available: the TIMP3 knock-out mouse (Soboleva et al., 2003) and the 
S156C-TIMP3 knock-in mouse (Weber et al., 2002), both of which should greatly 
enhance our understanding of the in vivo processes involved in this disease. At the same 
time, recombinant proteins were used to attribute precisely to TIMP3 the effects 
observed in the mouse models in an attempt to restore the lost TIMP3 protein and its 
biological function.  
 
4.1 TIMP3 involvement in the modulation of sheddase activity of 
TACE 
Many proteins are initially synthesized as membrane-anchored ligands that are 
subsequently cleaved from the surface of the cells, a process called shedding. It is an 
important post-translational mechanism for regulating the function of cell surface 
proteins (Hooper et al., 1997). This diverse group of proteins includes ligands such as 
cell adhesion molecules, growth factors and cytokines that undergo ectodomain 
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shedding of the membrane bound precursor to its soluble form. The membrane anchored 
proteins often have a different qualitative signal from that of the soluble ligand 
(Brannan et al., 1991; Grell et al., 1995; Suda et al., 1997). The sheddase activity can be 
provided by both membrane-bound as well as soluble proteases. Members of the zinc 
dependent membrane type MMPs (MT-MMP) and ADAMs have been identified as 
being responsible for shedding of the membrane bound proteins identified so far. In 
addition, soluble proteases such as neutrophil elastase, cathepsin G, and proteinase-3 
have been involved in the cleavage of the cell surface proteins (Bank & Ansorge, 2001). 
Among these proteases, ADAM17 (TACE) has emerged as an important mammalian 
ectodomain sheddase (Black, 2002; Peschon et al., 1998). The importance of TACE in 
the shedding process was demonstrated by deleting its catalytic domain in mice (Black 
et al., 1997). The TACE knock-out mice are not viable and display multiple 
developmental malformations (Peschon et al., 1998). Moreover, cells derived from 
TACE deficient mice show lower rates of release of TNF-α, as well as many other cell 
surface ligands. It has also been reported that the release of TNF-α from the cell surface 
can be achieved in vivo by MMP7 (Haro et al., 2000) and in vitro by MT1-MMP, MT2-
MMP (d'Ortho et al., 1997) and MT4-MMP (English et al., 2000). 
Proteolytic activity of TACE is precisely regulated by different mechanisms. At the 
transcriptional level, TNF-α stimulates expression of TACE mRNA in a positive feed-
back manner accompanied by increased TNF-Receptor I (p55) shedding (Bzowska et 
al., 2004). At the posttranslational level, the enzyme is synthesized as a zymogen with 
an N-terminal prodomain which confers latency. In order to become catalytically active 
the prodomain of TACE must be released and cleavage of the propeptide is performed 
by furin or a furin-like protease (Peiretti et al., 2003; Schlöndorff et al., 2000). The 
second mechanism by which TACE catalytic activity is controlled is performed by an 
endogenous inhibitor of many matrix proteinases namely TIMP3. Although TIMP3 
belongs to a class of inhibitors with four known members (TIMP1, -2, -3, -4), which 
have largely overlapping inhibitory activities, only TIMP3 is able to specifically block 
the cleavage activity of TACE (Amour et al., 1998). In vivo the role of TIMP3 in the 
inhibition of TACE mediated release of TNF-α has been demonstrated by deletion of 
TIMP3 gene. Mice deficient for TIMP3 show uncontrolled TNF-α shedding leading to 
chronic hepatic inflammation and failure of liver regeneration (Mohammed et al., 
2004). This indicates that TIMP3 is an important endogenous negative regulator for 
release of the proinflammatory cytokine TNF-α both in health and disease.  
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TNF-α is a pleiotropic cytokine and it has been implicated in a wide range of human 
disease including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid 
arthritis, and inflammatory bowel disease (Chen and Goeddel, 2002). Proinflammatory 
TNF-α produced by monocytes positively correlated with the prevalence of choroidal 
neovascularization in patients suffering from AMD (Cousins et al., 2004). AMD is a 
principal cause of blindness and has a pathology closely resembling that of SFD. It has 
also been reported that in a mouse model of AMD macrophages and inflammation play 
an active role in the development of disease characteristics (Ambati et al., 2003). 
Quantification of constitutive TNF-α shedding in the TIMP3 deficient mice 
demonstrated that the amount of cytokine is elevated in the liver (Mohammed et al., 
2004), whereas in several other organs such as spleen, lung, brain or serum the amount 
of protein shed was not altered compared to the WT counterpart. At the transcriptional 
level TNF-α mRNA levels were not influenced by TIMP3 deletion, and TACE 
transcripts in the retina are at the same level in both the knock-out and knock-in animals 
(Andreas Janssen, personal communication). These experimental data suggest tissue-
specific regulation of TACE mediated TNF-α shedding. Based on the available 
experimental data it was decided to investigate the effect of the S156C-TIMP3 mutant 
on TACE activity in the livers of gene targeted mice. Results from the present study 
reproduce the data from another report (Mohammed et al., 2004) showing that TACE 
activity in the liver of TIMP3 deficient mice is increased. The present study was 
directed towards understanding what effect the SFD mutation (S156C-TIMP3) has on 
TACE mediated TNF-α shedding. In this context, the S156C mutation (which is 
localized to the C-terminal domain of TIMP3) does not lead to significant modification 
of the inhibitory activity of TIMP3 towards TACE as measured by hydrolysis of the 
fluorogenic substrate. This is as expected as it is widely accepted that the N-terminal 
domain of the TIMP3 molecule is mainly involved in matrix metalloproteinases 
inhibition (Lee et al., 2002a, Langton et al., 1998, Kashiwagi et al., 2001, Lee et al., 
2002b). Moreover, a recent report, shows that the full-length and N-terminal domain of 
TIMP3 display equal inhibitory activities toward TNF-α convertase (Lee et al., 2001). 
Although, TIMP3 is the only native inhibitor of TACE, transplantation of several 
critical residues from TIMP3 to TIMP4 led to the conversion of a previously inactive 
inhibitor of TACE to an active inhibitor of this metalloenzyme (Lee et al., 2002; Lee et 
al., 2004; Lee et al., 2005). All the SFD related mutations identified are localized to the 
C-terminal domain of TIMP3, and therefore would not be expected to have any effect 
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on its inhibitory activity towards TACE (Lee et al., 2001). Furthermore, a nonsense 
mutation has been identified in a patient which introduces a premature stop codon at 
amino acid 139 (E139X). This mutation generates a protein corresponding to the N-
terminal domain of TIMP3 with the entire C-terminal domain deleted. Reverse 
zymogrphy using this truncated TIMP3 shows that it retains its inhibitory activity 
towards the gelatinolytic MMPs (Langton et al., 2000; Langton et al., 2005). Assuming 
that the mutation causes missfolding of the TIMP3 proteins (see later for discussion), 
from the results obtained it seems that the oligomeric protein has on its surface the 
residues important for the inhibition of matrix metalloenzymes. Therefore, these data 
argue against a loss-of-function mutation in the TIMP3 molecule towards TACE 
inhibition. 
 
4.2 Regulation of ADAMTS4/ADAMTS5 and MMPs proteolytic 
activity by TIMP3 
Excessive catabolism of cartilage ECM is a characteristic feature of arthritic 
diseases and is mediated by two classes of protease: MMPs and ADAMTS. These 
proteolytic enzymes degrade the two major structural components of cartilage 
extracellular matrix, namely collagen type II and the proteoglycan aggrecan (Clark et 
al., 2003) which together represent 90 % of the dry weight of cartilage. The aggrecan 
molecule can be cleaved at several distinct sites by other members of the ADAMTS 
family (Arner, 2002), but pathological cleavage by  ADAMTS4 and ADAMTS5 takes 
place at the position G373/A374 (Tortorella et al., 1999; Caterson et al., 2000; Mercuri 
et al., 1999; Tortorella et al., 2000; Arner et al., 1999) which has been called the 
aggrecanase site. Another cleavage site which is recognised by the MMPs (e.g. MMP1, 
2, 3, 7, 9, and 13) is located in the interglobular region of aggrecan at the position 
D341/F342 (Flannery et al., 1992; Fosang et al., 1992; Fosang et al., 1993; Fosang et 
al., 1996; Little et al., 1999; Chambers et al., 2001; van Meurs et al., 1999).  
Collagen type II is the second most important structural protein of cartilage and its 
damage is correlated with chronic arthritic diseases. This type of collagen together with 
aggrecan gives cartilage the strength to resist to high loads. The collagen matrix can be 
pathologically degraded by two mechanisms; either mechanical overloading (Radin et 
al., 1984; Randin and Rose, 1986) or cleavage of the collagen by collagenases-1 
(Pelletier et al., 1983; Whitham et al., 1986), collagenase-2 (Hasty et al., 1990; 
Devarajan et al., 1991) or collagenase-3 (Mitchell et al., 1996; Reboul et al., 1996). 
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Collagens can also be catabolised by non-collagen proteases such as cathepsins B, K 
and L (Maciewicz et al., 1990, van Noorden et al., 1991). 
Cartilage catabolism due to proteolytic enzymes can be assessed using neoepitope 
biomarkers. For this purpose specific types of antibodies, called neoepitope antibodies, 
have been developed which are able to recognise the short amino acid sequence exposed 
after cleavage by a specific proteinase. Some of these antibodies can be used to monitor 
the severity and the progression of articular cartilage break-down in a sandwich ELISA 
(Downs et al., 2001). 
MMPs cleavage of the aggrecan molecule at position N341/F342 generates the C-
terminal sequence DIPEN and an N-terminal fragment FFGVG. Cleavage by 
aggrecanases usually generates C-terminal NITEGE and N-terminal ARGSV 
neoepitopes, although ADAMTS4 and ADAMTS5 can also cleave the aggrecan at other 
sites as depicted in figure 15. The DIPEN neoepitope generated by MMPs and the 
NITEGE neoepitope generated by aggrecanases are retained in tissue bound to 
hyaluronan, whereas the corresponding FFGVG and ARGSVI neoepitopes are released 
from the articular cartilage (Fosang et al., 2003). MMPs derived FFGVG neoepitope 
fragments can be detected in human synovial fluids and so represent a candidate 
biomarker for aggrecan degradation (Fosang et al., 1996). The primary cleavage site for 
triple helical collagen type II by collagenases is at position G775/L776 giving the 
characteristic ¾ and ¼ length α chain fragments which can then be further degraded by 
different proteases. Therefore, antibodies directed against specific neoepitopes are 
useful tools for quantification of the cleavage rate of protein substrates by specific 
proteinase(s). 
It has been shown that TIMP3 is a potent inhibitor of ADAMT4/ADAMTS5 mediated 
aggrecan cleavage (Kashiwagi et al., 2001, Gendron et al., 2003). TIMP1, 2, 4 are also 
able to inhibit these two enzymes but with much lower efficiency (Hashimoto et al., 
2001). In order to systematically analyse the effect of TIMP3 deficiency or the S156 
TIMP3 mutation on the activity of ADAMT4/ADAMTS5 and the MMPs a number of 
experimental approaches were employed to cover both transcriptional and 
posttranslational effects. At a transcriptional level, according to semiquantitative PCR, 
none of the transcripts tested were up- or downregulated. In an in vivo system based on 
isolated chondrocytes derived from gene targeted mice the neoepitope antibodies were 
used to determine the cleavage rate due to the aggrecanases or MMPs. Catabolism of 
the aggrecan substrate was not significantly affected either in the TIMP3 knock-out or 
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in the S156C-TIMP3 knock-in chondrocytes when compared to WT counterparts. A 
possible explanation for these results is that the other three TIMPs are able to 
compensate for the absence of TIMP3 in inhibition of ADAMTS4. This theory was 
supported by experiments using recombinant proteins which demonstrate that aggrecan 
cleavage can be reduced by all TIMPs, emphasising the redundant function of TIMPs. 
Zymographic analyses demonstrates that various SFD-TIMP mutants, including S156C-
TIMP3, retain their ability to inhibit gelatin degradation by MMP2 and MMP9 (Langton 
et al., 2000, Soboleva et al., 2003). S156C-TIMP3 also blocks aggrecan and collagen 
type II cleavage by MMPs to a similar extent to wild-type TIMP3, demonstrating that 
the S156C-TIMP3 protein remains an effective inhibitor of MMPs. 
Cultivated chondrocytes from TIMP3-deficient mice displayed similar MMPs-mediated 
aggrecan cleavage rates to WT chondrocytes. Immunohistochemical localization of 
aggrecan degradation products revealed no major difference in aggrecan cleavage 
neoepitopes in knee joints of mice lacking TIMP3 when compared to wild-type mice 
under induced acute conditions of inflammatory arthritis (Mahmoodi et al., 2005). 
However, in articular cartilage from TIMP3 knock-out mice 6 months or older, 
increased labelling for the MMP cleavage product was observed (Sahebjam et al., 2007) 
suggesting that an imbalance between TIMP3 and MMP activities in these mice 
develops over time in vivo. On the other hand, the aggrecan region cleaved by MMPs is 
not essential for the catabolism of proteoglycan during development (Little et al., 2005). 
The results from the present study suggest that TIMP3 is not crucial for the maintenance 
of cartilage integrity and SFD TIMP-3 mutant blocks the catalytic activities of these 
enzymes with the same efficiency as the WT-TIMP-3. These data suggest that either the 
mutation in TIMP-3 molecule is far from the interaction site between TIMP-3 and the 
inhibited enzymes or the inhibitory function is taken over by the other TIMP family 
members. 
 
4.3 TIMP3 and angiogenesis 
The growth of blood vessels is an essential process for organ growth and repair 
and deregulation of angiogenesis contributes to many pathological condition including 
tumour spreading, inflammation, ischemic, infectious and immune disorders (Carmeliet, 
2003). Pathological angiogenesis of the retina is a serious condition which leads to 
irreversible loss of vision and is associated with a number of different retinal 
degenerative conditions. 
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The SFD mutation S156C was originally identified in a family with relatively early 
onset of symptoms in the third decade of life with choroidal neovascularisation as an 
important feature (Felbor et al., 1995). Relative recently, a direct association between 
TIMP3 and neovascularisation has been shown. Qi et al., 2003 demonstrated that 
TIMP3 is able to block angiogenesis by competing with VEGF for binding to VEGFR2, 
inhibiting downstream signalling which otherwise would lead to the initiation of new 
blood vessel formation.  
Results from the present study show that the S156C mutation does not have a 
significant effect on the capacity of TIMP3 to bind to VEGFR2 compared to WT 
recombinant protein, suggesting that the mutant protein retains its antiangiogenic 
property. Although one of the characteristics of SFD is neovascularization, the 
unaffected ability of the mutant TIMP3 to compete for VEGFR2 binding suggests that 
this angiogenic feature is not the primary cause which triggers the onset of the disease 
phenotype, but it may contribute at a later stage to aggravate the disorder. 
 
4.4 TIMP3 interaction with ECM components 
The extracellular matrix is a highly organized structure consisting of a complex 
mixture of proteins and polysaccharides which has not only a structural scaffolding role 
but also biochemical signalling properties. All of the biochemical components of the 
ECM are secreted locally by resident cells and there is a reciprocal influence. The 
interplay of cells with the surrounding matrix is mediated by cell surface receptors and 
coreceptors which modulate cell behaviour. Thus, upon receiving a specific signal, the 
cell can proliferate, migrate, differentiate, enter apoptosis or undergo morphogenesis.  
One of the major protein components of extracellular matrix are members of the large 
collagen family, originally thought to be only involed in the maintenance of the 
structural integrity of tissues and organs. Recently, it has become apparent that different 
types of collagens have a more complex function than simply scaffolding. Non-
collagenous fragments of collagens IV, XV and XVIII can influence angiogenesis, 
tumourigenesis, proliferation, apoptosis or survival and suppresses various 
morphogenetic pathways (Ortega & Werb, 2002; Davis et al., 2000; O'Reilly et al., 
1997). 
As the prime molecular mechanism which gives rise to the characteristics of SFD is still 
not fully understood, a search for new interacting partners for TIMP3 was undertaken in 
an attempt to gain insight into the pathomechanism of SFD. As the collagens are the 
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major insoluble fibrous protein component of the extracellular matrix and TIMP3 is the 
only family member which tightly binds to the ECM it seemed reasonable to analyse the 
interaction of TIMP3 with different collagens. The binding of TIMP3 to collagens was 
performed both in solution and with the collagens immobilized by adsorption to a solid 
surface. Using both procedures TIMP3 showed binding to five different types of 
collagen. Unexpectedly, when performing the same experiment using negative controls 
for TIMP3 binding (BSA and TTR), TIMP3 also bound to the negative control proteins 
as well. In an effort to dissect the molecular basis for this apparent unspecific binding of 
TIMP3 to the BSA, the two domains of TIMP3 (C-terminal and N-terminal) were 
expressed separately, purified and refolded. Analysis of the binding of TIMP3 domains 
to collagens and BSA revealed that the C-terminal domain was responsible for this 
apparent unspecific binding, while the N-terminal did not contribute significantly to the 
interaction. Interestingly, the C-terminal domain of TIMP3 bound to collagen with 
higher affinity than the full length protein. Therefore, the binding of TIMP3 to different 
ECM molecules is mediated by the C-terminal domain of the inhibitor. In this context, 
in the literature it has been described that TIMP3 heterologously expressed in 
mammalian cells was able to bind to elastin, laminin, fibronectin, collagen type I and 
IV, but the negative control represented by an unrelated protein was omitted (Majid et 
al., 2006). Recently, a yeast two hybrid screen has identified TIMP3 as a strong binding 
partner for EFEMP1 (Klenotic et al., 2004) and the binding between the two proteins 
was confirmed in solution by coimmunoprecipitation. This interaction is also mediated 
by the C-terminal domain of TIMP3. The authors of this report found the interaction 
between TIMP3 and EFEMP1 interesting because the EFEMP1 is mutated in another 
retinal degenerative disease (Malattia Leventinese or Doyne honeycomb retinal 
dystrophy) which shares a common pathological phenotype with SFD despite differing 
underlying molecular defects. However, in the absence of a negative control to which 
TIMP3 does not bind it is difficult to interpret the significance of these interactions. 
 
4.5 S156C-TIMP3 mutant oligomerization and aggregation 
 Most of the SFD causing mutations in the TIMP3 molecule generate free cys 
residues, and all are localized to the C-terminal region of the inhibitor. For secreted 
proteins in the extracellular space formation of disulfide bonds between cysteine 
residues are important to stabilize the correctly folded conformation of proteins (Raina 
& Missiakas, 1997). Therefore, a free cysteine residue in the TIMP3 molecule could 
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potentially disturb folding of the protein either by intrachain non-native disulfide bond 
formation or by building up oligomeric structures via intermolecular disulfide bonds. 
Several independent TIMP3 mutant molecules have been expressed in a variety of cells 
for analyzing disulfide linked oligomerazition. Thus, S156C, G166C, G167C, Y168C 
and S181C mutant TIMP3 have been expressed in COS-7 cells (Langton et al., 1998; 
Langton et al., 2000) or baby hamster kidney (BHK) cells (Yeow et al., 2002). Using 
this mammalian overexpression system it has been shown that these TIMP3 mutants are 
able to form dimers and oligomers. In contrast, expression of the S156C-TIMP3 mutant 
in ARPE-19 cells failed to demonstrate higher molecular weight complexes (Qi et al., 
2002) however, analysis of endogenous mutant TIMP3 under control of the natural 
promoter revealed that mutant TIMP3 forms high molecular weight complexes both in 
the patients fibroblasts (Arris et al., 2003; Weber et al., 2002) and fibroblasts derived 
from mice carrying S156C mutation (Weber et al., 2002; Soboleva et al., 2003). In this 
study further evidence is presented for the existence of disulfide bond mediated dimers 
in fibroblasts from the mutant mouse. As well as TIMP3 dimers aggregates of mutant 
TIMP3 can be observed at the top of the gel and which can be converted to the 
monomeric form by adding a reducing agent. This proves that the formation of 
aggregated protein is mediated by interchain disulfide bonds. This implies that the high 
molecular weight complexes are a common feature of the SFD associated TIMP3 
mutants, which is a widely accepted pathological characteristic of the SFD. 
As it has been shown so far that the mutant TIMP3 retains its normal biological 
functions, it was reasonable to analyze the functional consequences of the oligomeric 
structure of the mutant TIMP3. Quantification of mutant TIMP3 protein both in ECM 
and in cells revealed that a possible consequence of oligomerization is accumulation of 
the mutant TIMP3 in higher amounts than in WT-TIMP3 fibroblasts. The amount of 
mutant TIMP3 was elevated in both KI heterozygous and KI heterozygous animals, but 
there was no significant difference in levels between the two S156C knock-in cell lines. 
Furthermore, determination of TIMP3 turnover in the ECM showed that in the two KI 
cell lines the mutant TIMP3 is degraded at a slower rate than the wild-type protein, a 
result that is supported by another report (Langton et al., 2005) although in these 
experiments heterologously expressed mutant TIMP3 was used. The present data 
suggest that the mutation in the TIMP3 molecule causes an impairment of turnover of 
TIMP3 in the ECM and leads to its accumulation. This conclusion is supported by the 
fact that at transcriptional level the mutation in the TIMP3 gene does not have any 
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effect on the transcript production (Chong et al., 2003) so that the probable explanation 
for the higher amounts of mutant TIMP3 found in the two compartments is that the 
protein is aggregated and is resistant to proteolytic degradation. 
 
The accumulation of protein aggregates intracellularly and in the extracellular matrix is 
a predominant feature of many age related neurodegenerative diseases including 
Alzheimer’s, Parkinson’s, Huntington’s, Prion (Haass & Solkoe, 2007) and 
amyotrophic lateral sclerosis (Bruns & Kopito, 2007). Protein aggregates are oligomeric 
complexes of non-native conformers that arise from non-native homomeric or 
heteromeric interactions (Wetzel, 1994; Haase-Pettingell & King, 1998; Kopito, 2000). 
The aggregated proteins can further organise in higher order structures which are 
microscopically distinct cellular regions into which aggregated proteins are sequestered 
(inclusion bodies) (Kopito, 2000) which are sometimes called aggresomes (Johnston et 
al., 1998). Besides the major aggregated protein species the  aggresome contains other 
molecules including the chaperone Hsc70, the Hsp40 proteins Hdj1 and Hdj2, the 
chaperonin TriC/TCP (García-Mata et al., 1999; Wigley et al., 1999) and proteasome 
subunits 19S and 26S (Wójcik et al., 1996; Wójcik 1997; Fabunmi et al., 2000; Antón 
et al., 1999). Microscopically, aggresomes are usually localized in a pericentriolar 
structure, in close proximity to the nucleus (Johnston et al., 1998, Laszlo et al., 1991; 
Vidair et al., 1996; Brown et al., 1994). Protein aggregates associated with 
neurodegenerative diseases and deposited in the form of inclusion bodies can lead to 
impairment of the Ubiquitin-Proteasome System (UPS) (Bence et al., 2001). The UPS 
plays an important role in the maintenance of cellular quality control by degrading 
missfolded, unassembled or damaged proteins (Ciechanover et al., 2000). Impairment 
of UPS function by aggregation-prone proteins has been observed in a number of 
neurodegenerative diseases including a huntingtin fragment containing a pathogenic 
polyglutamine repeat and a folding mutant of cystic fibrosis transmembrane 
conductance regulator (Bence et al., 2001; Bennett et al., 2005; Bennett et al., 2007). 
Mutations linked to autosomal dominant retinitis pigmentosa results in the production of 
a missfolded and highly aggregation-prone form of rhodopsin that can inhibit UPS 
function (Saliba et al., 2002; Illing et al., 2002; Rajan & Kopito, 2005). This would 
suggest that retinal degeneration may share common pathogenic features with other 
adult onset degenerative diseases of the central nervous system. 
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The results from the present study demonstrate that the biological functions of TIMP3 
are not affected by S156C mutation in TIMP3 molecules associated with SFD. On the 
other hand, the consequence of the mutation can be observed in protein missfolding 
which leads to aggregation of mutant TIMP3 and finally to accumulation in the cell and 
in the extracellular matrix. Taken together, it seems plausible to suggest that the 
pathomechanism is not due to a loss-of-function, but rather a toxic gain-of-function and 
it can be supposed that TIMP3 might be missfolded and accumulate in the ECM. 
Therefore, it is reasonable to propose that the missfolded form of mutant TIMP3 is the 
initial major cause of the SFD disorder. This possibility would classify SFD in the 
category of conformational diseases (Kopito & Ron, 2000) specific for 
neurodegenerative disorders. 
 
In summary, this work addresses the question of whether the effect of the Ser156Cys-
TIMP3 mutant in SFD is due to haploinsufficiency or a dominant negative effect. 
Examination of the inhibitory activity of TIMP3 mutant towards the MMPs, 
ADAMTS4/ADAMTS5 and TACE indicates that the pathogenic mutation has no effect 
on the enzymatic activities, implying that the mutation has a dominant negative effect. 
This assumption is suported experimentally when the turnover of mutant TIMP3 vs. WT 
TIMP3 is compared; the mutated TIMP3 tends to form higher molecular weight 
oligomers, accumulates in the cell and ECM and appears to be significantly more 
resistant to ECM turnover. 
 
Further studies are required to completely elucidate the SFD pathomechanism and the 
primary molecular events which trigger initiation of the disease. Identifying the initial 
molecular processes involved in SFD pathology could potentially indicate therapeutic 
target(s) and facilitate the development of an effective therapeutic agent which could 
slow down or stop disease progression. One molecular mechanism which needs further 
investigation is the protein accumulation/aggregation of mutant TIMP3 and its 
consequences on SFD pathology. If the protein aggregation plays a role in the 
pathomechanism of SFD that would not be surprising as a number of neurodegenerative 
diseases have this molecular cause.  
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5. Summary 
Sorsby fundus dystrophy (SFD) is an autosomal dominant disorder of the central 
retina (Sorsby et al., 1949). It is characterized by subretinal neovascularization, atrophy 
of the retinal pigment epithelium and the choriocapillaris. It is a progressive disorder 
leading ultimately to blindness. Mutations in the TIMP3 molecule have been linked to 
SFD (Weber et al., 1994). So far, several point mutations have been identified in the 
TIMP3 molecule, all localized at the C-terminal domain of the inhibitor, the majority of 
which result in a single unpaired cysteine residue in the mature protein. TIMP3 belongs 
to a family of secreted proteins comprising four members (TIMP1, -2, -3, -4). TIMP3 is 
ECM (extracellular matrix) bound inhibitor with a molecular mass of 24 kDa having 12 
conserved Cys residues consisting of two domains which fold independently with 3 
disulfide bonds in each domain.  
TIMP3 is a multifunctional protein involved in the inhibition of matrix 
metalloproteinases (MMPs) (Murphy et. al., 1994). It can block the TACE (tumour 
necrosis factor (TNF)-alpha converting enzyme) (or ADAM17 - a disintegrin and 
metalloproteinase) mediated ectodomain shedding of pro-TNF-α (Amour et al., 1998), 
Syndecan-1 and Syndecan-4 (Fitzgerald et al., 2000), L-selectin (Borland et al., 1999), 
and interleukin-6 receptor (Hargreaves et al., 1998). TIMP3 is also involved in the 
inhibition of the ADAMTSs (a disintegrin-like and metalloproteinase with 
thrombospondin type 1 motif) especially ADAMTS4, ADAMTS5 (Kashiwagi et al., 
2001) and ADAMTS2 (Wang et al., 2006). TIMP3 also blocks angiogenesis by binding 
to VEGFR2 (vascular endothelial growth factor receptor 2) (Qi et al., 2003) and also 
interacts with EFEMP1 (epithelial growth factor-containing fibulin-like extracellular 
matrix protein 1) (Klenotic et al., 2004). 
TIMP3 is unique among the TIMPs in that it can inhibit TACE mediated TNF-α 
shedding. We have measured TACE activity in liver extracts from mice deficient for the 
TIMP3 gene using cleavage of a fluorogenic substrate and found increased TACE 
activity. We were also interested to analyse the influence of the SFD mutation on the 
inhibition of TACE activity. The S156C mutation in the C-terminal domain of TIMP3 
does not lead to significant modification of the inhibitory activity towards TACE as 
measured in this assay.  
Another biological function of TIMP3 is its ability to block ADAMTS4/ADAMTS5 
(aggrecanase-1, aggrecanase-2) and MMPs mediated cleavage of aggrecan (Kashiwagi 
et al., 2001). TIMP3 influence on Aggrecan cleavage can be monitored by so-called 
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neoepitope antibodies – which recognize the newly created epitope after cleavage of the 
aggrecan by ADAMTS4/ADAMTS5 or MMPs. In a cell-based ELISA using 
chondrocytes it was found that cleavage activity of ADAMTS4/ADAMTS5 and MMPs 
towards aggrecan are not affected either in TIMP3 knock-out (KO) chondrocytes or 
S156C-TIMP3 knock-in (KI) chondrocytes compared to WT counterparts. 
It has been also demonstrated that TIMP3 is able to block angiogenesis by competing 
with VEGF for binding to VEGFR2 (Qi et al., 2003). We have also used recombinant 
proteins to analyse the antiagiogenic property of TIMP3 via its known function of 
competing with VEGF ligand for its receptor (VEGFR2). The results demonstrate that 
the S156C mutation in the TIMP3 molecule does not have a significant effect on its 
capacity to bind VEGFR2 compared to WT recombinant protein. 
As the pathomechanism of SFD is still unknown it seemed reasonable to search for new 
interacting partners which might help gain insight into the molecular basis of the 
disease. In this context, the ability of TIMP3 to bind several different types of collagens 
was tested. In an ELISA, recombinant TIMP3 was able to bind to five different types of 
collagens in a concentration dependence manner. In parallel, TIMP3 interacted with 
BSA and another unrelated protein (TTR), indicating that the interactions are apparently 
unspecific. These interactions are mediated by the C-terminal domain of TIMP3. 
Cysteine residues are required for the formation of disulfide bonds which stabilize the 
folded conformation of proteins (Raina et. al., 1997). Therefore, a free cysteine residue 
in the TIMP3 molecule could potentially disturb folding of the protein. To analyse this 
hypothesis we have performed western blotting and detected higher molecular weight 
complexes caused by intermolecular disulfide bonds. As fibroblasts from the S156C KI 
mouse were available we quantified the amount of mutant TIMP3 in heterozygous and 
homozygous immortalized cell lines. ELISA results showed increased amounts of the 
mutant protein compared to the WT in both the ECM and cells. We next tested if the 
accumulation of mutant protein is due to increased resistance of the misfolded protein to 
proteolytic degradation. TIMP3 turnover in the ECM, determined by ELISA, revealed 
that S156C-TIMP3 mutant does indeed have a slower turnover compared to the WT. 
These results indicate that the pathomechanism of SFD is not due to a loss-of-function, 
but rather a toxic gain-of-function caused by accumulation of misfolded mutant TIMP3 
in the ECM. Therefore, it is reasonable to conclude that the oligomeric form of TIMP3 
is the major cause of the SFD disorder. This would classify SFD in the category of 
conformational diseases specific for the neurodegenerative disorders. 
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6. Appendix 
 
Abbreviations 
 
ADAM A disintegrin and metalloproteinase 
ADAM-TS ADAM with trombospondin motifs 
AMD Age-related macular degeneration 
Amp Ampicillin 
APS Ammonium persulfate 
Ax Absorption at x nm 
bp Base pairs 
BSA Bovine serum albumin 
CD Catalytic domain 
cDNA Complementary DNA 
DAPI 4’,6-Diamidin-2’-phenylindol-dihydrochloride 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
dNTPs Deoxynucleotide triphosphates 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
FRET Fluorescence resonance energy transfer 
GFP Green fluorescent protein 
GST Glutathione S-transferase 
GusB 
Het 
Hom 
β-glucuronidase 
Heterozygous 
Homozygous 
IMAC Immobilized metal affinity chromatography 
IPTG Isopropyl-β-D-thiogalactopyranoside 
KD Dissociation constant 
kDa Kilo Dalton 
KI Knock-in 
KO Knock-out 
LB Luria Bertani  
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MMP Matrixmetalloproteinase 
MOPS Morpholinepropanesulfonic acid 
Ni-NTA Nickel-nitrilo triacetic acid 
ODx Optical density at x nm 
PBS Phoshate buffered saline 
PCR Polymerase chain reaction 
PVDF Polyvinylidene difluoride 
RNA Ribonucleic acid 
RPE Retinal pigment epithelium 
rpm Revolutions per minute 
SDS-PAGE Sodiumdodecylsulfate polyacrylamide gel electrophoresis 
TACE TNF-α converting enzyme 
TEMED N,N,N‘,N‘-tetramethylene diamine 
TIMPs Tissue inhibitor of matrix-metalloproteinases 
TNF-α Tumour necrosis factor alpha  
Tris Tris-(hydroxymethyl)-aminomethane 
U Unit (measure of enzyme activity) 
v/v Volume per volume 
VEGF Vascular endothelial growth factor 
VEGFR2 Vascular endothelial growth factor receptor II 
w/v Weight per volume 
WT Wildtype 
β-ME β-mercaptoethanol 
 
 
List of oligodeoxynucleotides used in the present study 
 
Sequencing primers 
pCEP4_new-F 5'-GGACTTTCCAAAATGTCGTAATAA-3' 
pCEP4_new-R 5'-CAAATAAAGCAATAGCATCACAAAT-3' 
pET_F 5'-ATACGACTCACTATAGGGG-3' 
pET_R 5'-TAGTTATTGCTCAGCGGTG-3' 
M13-F 5'-CGCCAGGGTTTTCCCAGTCACGAC-3' 
M13-R 5'-AGCGGATAACAATTTCACACAGGA-3' 
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Seq_p_pEGFP-C1_F 5'-AATGTCGTAACAACTCCGCC-3' 
Seq_p_pEGFP-C1_R 5'-TATGTTTCAGGTTCAGGGGG-3' 
pcDNA3-R 5'-TAGGGCCCTCTAGATGCATG-3' 
pcDNA3-F2 5'-CACTGCTTACTGGCTTATCG-3' 
pGEX_F 5'-GGGCTGGCAAGCCACGTTTG-3' 
pGEX-R 5'-CCGGGAGCTGCATGTGTCAGAGG-3' 
pFLAG-F 5'-CGTGTACGGTGGGAGGTCTA-3' 
pFLAG-R 5'-TTATTAGGACAAGGCTGGTG-3' 
 
RT-PCR primers 
Sq_Agc_F 5'-GTCCCCTGCAATTACCAGC-3' 
RT_Agc_R 5'-GCCTGTGCTTGTAGGTGTTG-3' 
Sq_Adamts4_F 5'-GCACTGGGCTACTACTACG-3' 
RT_Adamts4_R 5'-GGCCAGGTAGATGCTCTTGA-3' 
Sq_Adamts5_F 5'-GAGAACTGGATGTGACGGC-3' 
Sq_Adamts5_R 5'-CGGTACCATTGATGTCGATG-3' 
GUSB3 5'-ACTATCGCCATCAACAACACACTGACC-3' 
GUSB5R 5'-GTGACGGTGATGTCATCGAT-3' 
 
Cloning primers 
Timp1_N_F 5'-GCTAGCCATATGTGTAGCTGTGCCCCACCC-3' 
Timp1_C_R 5'-GCTAGCCTCGAGTCGGGCCCCAAGGGATCTC-3' 
Timp2_N_F 5'-GCTAGCCATATGTGCAGCTGCTCCCCGGTG-3' 
Timp2_C_R 5'-GCTAGCCTCGAGCGGGTCCTCGATGTCAAG-3' 
Timp3_N_F 5'-GCTAGCCATATGTGCACATGCTCTCCCAGCC-3' 
Timp3_N_R 5'-GCTAGCCTCGAGATTGCAACCCAGGTGGTAGC-3' 
Timp3_C_F 5'-GCTAGCCATATGTGCAAGATCAAGTCCTGC-3' 
Timp3_C_R 5'-GCTAGCCTCGAGGGGATCTGTGGCGTTGCTG-3' 
Timp4_N_F 5'-GCTAGCCATATGTGCAGCTGTGCGCCTGCG-3' 
Timp4_C_R 5'-GCTAGCCTCGAGGGGCTGGATGATGTCAACG-3' 
TACE_CD_pET_F 5'-GACGCTCATATGCGAGCTGAACCTAACCCCTTG-3' 
TACE_CD_pET_R 5'-GGCAGCCTCGAGCACCTTGTTGCTGCGCTCC-3' 
Pept_GA_F 5'-CCGCGTGGATCCGGGGTGGGTGGTGAAGACG-3' 
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Pept_GA_R 5'-
CACGATGCGGCCGCTCAAGGGGCAAGTGTGAGGGCC-3' 
Pept_Gm_F 5'-CCGCGTGGATCCGGGGTGGGTGGTGAAGACG-3' 
Pept_Gm_R 5'-
CACGATGCGGCCGCTCACTCTCCCTCTGTGACATTAC-3' 
Pept_Gh_F 5'-CCGCGTGGATCCCATCACCGTCCAGACAGTG-3' 
Pept_Gh_R 5'-
CACGATGCGGCCGCTCATTCACCCTCAGTGATGTTTCG-3' 
MMP13_F 5'-GTAGCTAGCTATGGTGATGATGATGATGATGACC-3' 
MMP13_R 5'-CTACTCGAGACACCACAATATGGAATTTGTTGGC-3' 
Agc_E_F 5'-CCGCGTGGATCCTCTGTTTCTGGGGTAGGTG-3' 
Agc_E_R 5'-
CACGATGCGGCCGCTCAACTAATGTCCGCACTACTGTC-3' 
Adamts4_E_F 5'-CCGCGTGGATCCGCTGCCTACAACCACCGAAC-3' 
Adamts4_E_R 5'-CACGATGCGGCCGCTCATTGGTCTCGAGGGGCC-3' 
 
List of plasmids employed in the study 
pET-21a(+) Novagen; Studier et al., 1990 
pLysS Novagen, Studier et al., 1990 
pGEX-4T3 Amersham Biosciences 
pGEM Promega 
pcDNA3 Invitrogen 
pCEP4 Invitrogen 
pEGFP-C1 Clontech 
pFLAG-CMV Sigma 
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